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ABSTRACT 
PGE2 RECEPTOR SUBSETS MEDIATE HCG REGULATION OF THE 
PLASMINOGEN ACTIVATOR/PLASMIN SYSTEM IN PRIMATE 
PERIOVULATORY FOLLICLES 
Nune Markosyan 
Eastern Virginia Medical School and Old Dominion University 
Director: Dr. Diane M. Duffy 
Elevated follicular prostaglandin E2 (PGE2) levels are necessary for follicle 
rupture during ovulation. As the degradation of the follicle wall requires proteolysis, it 
was hypothesized that regulation of proteolysis by gonadotropins is PGE2 mediated. 
There are four PGE2 receptors: EP1, EP2, EP3 and EP4. To determine which 
PGE2 receptors are present in monkey periovulatory follicles, granulosa cells and whole 
ovaries were collected 0, 12, 24, and 36 hours after administration of an ovulatory dose of 
human chorionic gonadotropin (hCG), or 36 hours after hCG from monkeys that received 
the prostaglandin (PG) synthesis inhibitor celecoxib. All EP receptor mRNAs were 
present in granulosa cells. By immunofluorescence, EP1 was detectable only 36 hours 
after hCG. EP2 and EP3 proteins were present throughout the periovulatory interval. By 
western blotting, EP2 and EP3 proteins increased between 0 and 36 hours after hCG. EP4 
protein was not detected in periovulatory granulosa cells. An increase in EP2 and EP3 
receptor responsiveness was confirmed by measuring elevated cAMP levels in response 
to receptor selective agonists. EP1 receptor function, measured as an increase in 
intracellular calcium, was present only 36 hours after hCG administration. 
To elucidate the role of the ovulatory gonadotropin surge and PGs in the 
regulation of periovulatory proteolytic events, the expression of mRNA and protein for 
the tissue type plasminogen activator (tPA) and urokinase type plasminogen activator 
(uPA) and their inhibitor PAI-1 was measured in granulosa cells. uPA and PAI-1 
mRNAs peaked 12 hours and 36 hours after hCG administration respectively. tPA 
mRNA decreased 36 hours after hCG. Celecoxib administration had no effect on any of 
these mRNAs. By immunofluorescence, tPA and PAI-1 protein expression increased 12 
hours after hCG and persisted until 36 hours after hCG. tPA and PAI-1 proteins were not 
detectable 36 hours after hCG in celecoxib treated animals. uPA was not detectable in 
granulosa cells before and after hCG administration. By in situ zymography, 
plasminogen activator (PA) activity was low before hCG administration and detectable 
12, 24 and 36 hours after hCG. PA activity was attenuated by pre-incubation with an 
anti-tPA antibody. Animals treated for 36 hours with hCG+celecoxib had low ovarian 
PA activity. To determine whether PGE2 is the key PG in the regulation of PA family 
members, 0 hour granulosa cells were hCG treated with or without PGE2 or EP receptor 
selective agonists. tPA protein increased only in the presence of PGE2, the EP2 agonist 
or the EP3 agonist. PAI-1 protein was detected in cells cultured with PGE2, the EP1 
agonist or the EP3 agonist. 
These studies demonstrate that the ovulatory gonadotropin stimulates granulosa 
cell EP receptor expression and responsiveness. PGE2, acting through EP2 and EP3 
receptors, may mediate the hCG induced increase in tPA proteolytic activity. 
Taken together, this study elucidates the mechanisms by which the ovulatory 
gonadotropin surge and PGE2 cooperate to regulate proteolysis in the periovulatory 
follicle. This information may lead to improved treatments for anovulation or to the 
development of new contraceptive options. 
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The release or surge of luteinizing hormone (LH) by the pituitary gland initiates 
events in the dominant follicle that will lead ovulation, or the release of a mature oocyte. 
Prostaglandins (PGs) produced by the ovarian follicle during the interval between the LH 
surge and ovulation (the periovulatory period) are essential for ovulation to occur. 
Classical "ablate and replace" experiments have identified PGE2 as the key ovulatory 
prostaglandin in several mammalian species. 
The actions of PGE2 are mediated by four different receptors: EP1, EP2, EP3 and 
EP4. The expression and function of EP receptors have been studied in different tissues 
of various species. Successful ovulation requires functional EP receptors to mediate the 
ovulatory effects of PGE2. However, very little is known about EP receptors and their 
function in the primate ovary and, more specifically, in the granulosa cells of 
periovulatory follicles. 
Oocyte release at ovulation requires extensive breakdown and remodeling of the 
fibrinous and collagenous connective tissue layers of the mammalian follicle. Many 
studies suggest that serine proteases of the plasminogen activator (PA) /plasmin system 
play a crucial role in follicle wall rupture. Tissue type PA (tPA) and urokinase-type PA 
(uPA) act on plasminogen to convert it into the active proteolytic enzyme plasmin, which 
degrades extracellular matrix directly or by activation of other proteases. The PA 
inhibitor type-1 (PAI-1) is an important regulator of PA dependent proteolysis. The 
The journal, Endocrinology, was used as a model for this dissertation. 
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synthesis and release of both PAs and their inhibitor are modulated by hormones, growth 
factors and cytokines. Studies in various species indicate that the expression and activity 
of PAs and their inhibitor may be regulated by the ovulatory surge of gonadotropin to 
insure that the follicle wall ruptures just before the expected time of ovulation. However, 
several studies suggest that other signaling molecules like PGs may mediate the ability of 
gonadotropin to regulate proteolysis in periovulatory follicles. Inhibition of PG synthesis 
by intrafollicular indomethacin injection prevented follicle wall rupture while co-
administration of indomethacin and PGE2 restored ovulation, supporting a pivotal role 
for PGE2 in the degradation of extracellular matrix. 
The objectives of this study are the following: 
1. Determine which EP receptors are expressed by primate granulosa cells during the 
periovulatory period. 
2. Determine which EP receptors are able to generate an intracellular response to PGE2 
and how EP receptor responsiveness is regulated during the periovulatory period. 
3. Determine if the expression of PAs and their inhibitor as well as the activity of 
PA/plasmin system are gonadotropin and PGE2 regulated in monkey periovulatory 
granulosa cells. 
4. Determine which PGE2 receptor(s) mediate the ability of gonadotropin to regulate the 
expression and activity of PAs. 
Elucidation of the mechanisms of PGE2 action during the periovulatory period and 
the effect of PGE2 on proteolytic degradation of the follicle wall may provide necessary 
background for the development of new contraceptives that will inhibit ovulation without 
affecting the steroid hormonal milieu or the development of the corpus luteum. In 
3 
addition, this study may identify a mechanism to explain the decreased fertility in women 




2.1 Follicular Development and Ovulation 
In neonatal females, the ovary contains primordial follicles. Each primordial 
follicle consists of an oocyte arrested in the prophase of the first meiotic division 
surrounded by a monolayer of flat pregranulosa cells. The primordial follicle is separated 
from surrounding stroma by a basement membrane (1). The growing oocyte synthesizes 
and secretes a mucoid substance containing glycoproteins that forms the zona pellucida, 
which separates the oocyte from the granulosa cell layer (2). The primordial follicle lacks 
blood vessels inside the basement membrane. The transfer of nutrients to the oocyte 
occurs by diffusion through protoplasmic processes from granulosa cells that penetrate 
and traverse the zona pellucida to establish contact with the plasma membrane of the 
oocyte (3). During follicular development, the oocyte continues to grow, and flattened 
granulosa cells are transformed into cuboidal cells to form a primary follicle. By a series 
of mitotic divisions, multiple layers of granulosa cells are formed, converting the primary 
follicle into a secondary or preantral follicle (4). Concurrent with proliferation of 
granulosa cells, stromal cells close to the basement membrane differentiate into theca 
interna cells while a portion of theca cells merge with the surrounding stroma and are 
transformed into theca externa (5). During subsequent follicular growth, proliferating 
granulosa cells secrete proteoglycans and gelatinous materials that form follicular fluid 
and transform the secondary follicle into an early antral follicle (6). The antral follicle has 
two distinct populations of granulosa cells: mural granulosa cells that line the basement 
membrane and cumulus granulosa cells that surround the oocyte (Figure 1). The further 
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Figure 1. Antral follicle. The large antral follicle 
consists of a fluid filled antrum, an oocyte 
surrounded by cumulus granulosa cells and mural 
granulosa cells that line basement membrane. 
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development of antral follicles is under the control of the pituitary gonadotropins follicle 
stimulating hormone (FSH) and LH (5). 
At each menstrual cycle, one (or occasionally, more than one) antral follicle from 
a cohort of developing follicles stimulated by pituitary gonadotropins matures to become 
the dominant follicle that will ovulate. Gonadotropins stimulate the synthesis of 
estrogens, androgens and progestins within the ovary. These steroids, along with 
gonadotropins, regulate the growth of the antral follicles by inducing receptors necessary 
for follicle survival, maturation and ovulation. The rising levels of estrogen produced by 
granulosa cells of the dominant follicle induce the anterior pituitary to release an 
ovulatory dose of LH known as the LH surge. The latter can lead to as much as a 100-
fold increase in the circulating level of LH (7). In the early 1970s, it was concluded that 
ovulation-inducing hormones consist of a mixture of FSH and LH (8). Other hormones 
like chorionic gonadotropin (CG), which has a peptide sequence that is highly 
homologous with LH, is commonly used as a substitute for LH (9). 
The ovulatory process is initiated at the moment when follicular cells are 
stimulated by the LH surge. The period between the LH surge and ovulation is known as 
the periovulatory period. The events described below are the changes that take place in 
the periovulatory follicle as described by Knobil (4). The follicle basement membrane 
breaks down, and the blood vessels penetrate into the follicle, which now is considered a 
periovulatory follicle. At this stage, the volume of follicular fluid increases as blood 
plasma transudes from the invading blood vessels. Theca cells, endothelial cells and other 
stromal elements migrate into granulosa cell layer along with the newly formed 
capillaries. Granulosa cells within the follicle stop proliferating and undergo hypertrophy. 
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Granulosa cells of mature preovulatory follicles contain some smooth endoplasmic 
reticulum, Golgi networks, granular mitochondria, and occasional lipid granules. In the 
periovulatory follicle, granulosa cells contain a greater number of lipid granules, which 
indicates increased steroidogenesis. After the ovulatory gonadotropin surge, the oocyte 
undergoes germinal vesicle breakdown, extrudes the first polar body and proceeds to the 
metaphase of the second meiotic cell division. Cumulus granulosa cells around the oocyte 
loosen their contacts with each other, secrete hyaluronic acid, and expand into the gel like 
matrix. The cumulus-oocyte complex (COC) detaches from the follicle wall; now the 
oocyte is ready for ovulation and fertilization. Parallel to above described events, ovarian 
stroma undergoes extensive breakdown specifically at the follicle apex. The 
periovulatory events culminate in follicle wall rupture and oocyte release, after which the 
follicle transforms into a corpus luteum to produce progesterone. 
Mammalian ovulation is a unique physiological process that requires the rupture 
of multiple layers of healthy tissue at the surface of the ovary. In most mammals, at the 
time of ovulation, the site of the imminent rupture on the follicle wall becomes very thin, 
almost transparent (10). Following rupture, the luteinizing follicle protrudes through the 
ovarian wall forming a so-called ovulatory stigmata. In species such as rabbit and sheep 
that form ovulatory stigmata, during the final stages of periovulatory period, the follicle 
wall begins to form a bulge on the surface of the ovary, the basement membrane between 
the granulosa cell layer and theca interna dissociates and forms invaginations into the 
granulosa cell layer (4). Multiple breaks form along the basement membrane, which 
allow the blood vessels to penetrate into the follicle. Because of the basement membrane 
invagination, the granulosa cell layer and vascular theca layer also dissociate from the 
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apex of the stigmata, leaving the thin stigmata wall without blood supply. The thin, 
avascular apex becomes almost translucent because of the enzymatic degradation of the 
collagenous tissue and finally ruptures, releasing the oocyte with the surrounding 
cumulus granulosa cells into the peritoneal cavity. Now, the collapsed postovulatory 
follicle is a newly forming corpus luteum (CL) and will become a highly vascularized 
endocrine gland that includes both the luteinizing granulosa cells and recently migrated 
theca cells (5, 11, 12). 
Over the past century, different theories have been proposed to explain the well-
orchestrated events that lead to ovulation. Some of these theories were proven wrong, and 
others have received some validation by experimental results. However, there is no single 
exhaustive theory that will explain all aspects of ovulation, suggesting that ovulation is a 
very complex physiological process which probably combines events described in 
various theories and requires further investigation for comprehensive understanding. 
2.1.1 Smooth muscle theory of ovulation 
Initial studies of ovulation were performed mainly in vivo, with observations 
made with the naked eye. The early theories about the mechanism of ovulation focused 
on the possible role of smooth muscle and the potential for such tissue to create 
intrafollicular pressure of sufficient magnitude to cause healthy follicular tissue to 
rupture. 
The smooth muscle theory of ovulation has been one of the most controversial 
issues in the field of reproductive physiology (4). At the beginning of the 20th century, 
von Winiwarter and Sainmont provided histological evidence of the presence of smooth 
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muscle cells in the cat and human follicle wall. As discussed by Knobil (4), they were 
unable to demonstrate that either electrical or chemical stimuli could cause the follicle to 
rupture. In 1919, Thomson carried out extensive histological studies and concluded that 
rhythmic muscular contractions on an enlarged and vascularized follicle naturally 
increase the intrafollicular pressure and cause the follicle to rupture. In 1964, during his 
doctoral studies, Espey conducted experiments to investigate the contractile ability of the 
cells that were identified as follicular smooth muscle cells. Using transmission electron 
microscopy, he examined the distribution of collagenous connective tissue and fibroblasts 
in the theca externa of the follicle and verified that follicular collagen fibers were able to 
contract when exposed to acidic solutions (13). As he described in a review, Espey found 
that strips of sow follicles would contract only in response to HC1, that such contractions 
were tetanic in nature (14). He also showed that the tissue would relax only if it was 
exposed to alkaline solutions, and that such contractility could be attributed to collagen 
fibrils in the thecal layers of the follicle. 
The smooth muscle controversy became more intense during the 1970s, when 
numerous new reports claimed that smooth muscle activity is an integral part of the 
ovulatory process. However, the observation was made that typical smooth-muscle cells 
are confined mainly to the hilar and medullary regions of the mammalian ovary (14). At 
the time of ovulation, thecal fibroblasts may differentiate into myofibroblasts to facilitate 
wound healing, but there is no convincing evidence that such cells have an essential role 
in the mechanism of ovulation. It is possible that the rhythmic contractions detected in 
the ovaries (15-17) were the consequence of vascular spasms in the blood vessels that 
enter the hilar region of the ovary. This could be promoted by an agent like prostaglandin 
F2ot (PGF2a), which stimulated contractions of ovarian arterial smooth muscle (18), and 
which increased markedly in the ovary during ovulation (19-21). A very recent study 
detected cells that stain for SMAa (smooth muscle actin) around individual follicles in 
mice (22). These cells formed an interconnected smooth muscle network at the ovarian 
level. The apical region of a periovulatory follicle, a putative site of follicle rupture, was 
not stained by the SMAa antibody, indicating absence of smooth muscle cells in the 
region. In the same study, contractile activity of ovarian tissue was evaluated by an 
isometric tension measurement approach. Endothelin-2 instantly induced contraction in 
ovarian tissue strips obtained from immature rats primed for superovulation. Endothelin-
2 mRNA was transiently increased in mural granulosa cells of the periovulatory follicles 
just before ovulation (23). Treatment with endothelin-2 receptor B (ETR-B) antagonist 
dramatically (>85%) decreased the number of released oocytes in mice, indicating that 
endothelin-2 induced contractions may be important for successful ovulation. 
In summary, there are still differing opinions about the extent to which smooth 
muscle cells are distributed in and around mammalian follicles. Some investigators 
continue to believe that the theca externa consists of typical smooth muscle cells. Other 
studies report that the theca externa is a matrix of collagenous connective tissue with 
fibroblasts, not muscle cells, comprising the cellular component. Until recently, the 
consensus was that ovarian contractility is not a necessary feature of the ovulatory 
process, but there remains the possibility that some of the fibroblasts begin to 
differentiate into myofibroblasts as a ruptured follicle transforms into a corpus luteum. 
However, recent studies, which show the importance of the smooth muscle-contracting 
11 
compound endothelin-2 in ovulation, have revived the interest in the smooth muscle 
theory of ovulation. 
2.1.2 Pressure theory of ovulation 
At the beginning of 20th century, additional attention was given to the hypothesis 
that an increase in intrafollicular pressure might be responsible for rupture of a mature 
ovarian follicle (reviewed by Knobil (4)). In 1921, Wester suggested that some kind of 
pressure "necrosis" of the follicular wall was the final cause of rupture. However, the 
Guttamacher twins created in sow follicles unusually high intrafollicular pressures of 300 
to 350 mm Hg for hours without inducing ovulation. In 1932, Hartman reported that 
follicles of pigs, cattle and sheep become less tense a few hours before ovulation, and this 
fact does not favor the idea of an increase in intrafollicular pressure as a major stimulator 
of ovulation. 
Another version of the pressure theory was based on the idea that osmotic 
pressure might increase in ovarian follicles near the time of ovulation. In 1958, Zachariae 
and Jensen provided support for the osmosis hypothesis by reporting that preovulatory 
hyaluronidase activity depolymerized the acid mucopolysaccharides of the follicular 
fluid, "resulting in an increase in the intrafollicular colloid-osmotic pressure, increased 
volume, and follicular rupture" (reviewed in (4)). However, the presence of a follicular 
mucopolysaccharidase was never confirmed, and this theory of ovulation faded. 
Later studies excluded the role of hydrostatic pressure in ovulation (10). 
Intrafollicular pressure did not increase during ovulation but remained at a relatively 
constant 15 to 20 mm Hg that is dependent on the hydrostatic pressure in the extensive 
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capillary network of the theca interna. This moderate pressure may play role in the 
formation of the ovulatory stigmata, but it is not likely to be the key to ovulation as it 
does not explain the majority of observed changes in the follicle structure. 
2.1.3 Proteolytic enzyme theory of ovulation 
Gradual disappearance of the connective tissue at the stigma and the erosion of 
the rupture site described by the early investigators showed that ovulation was not 
explosive tearing of the follicle wall. In early studies, Schochet analyzed follicular fluid 
from large sow follicles and concluded that the fluid was the source of "a proteolytic 
ferment or enzyme" that contributed "to the digestion of the theca folliculi" (reviewed in 
(4)). His experiments were never confirmed by others, and it is doubtful that the follicular 
fluid is the source of the proteases that degrade the follicle wall. Despite this, Schochet is 
usually given credit for the proteolytic enzyme theory of ovulation. Later experiments by 
Rugh et al. in 1935 and Kraus et al. in 1947 showed that external application of pepsin 
solutions to frog ovaries caused erosion of the follicle wall (reviewed in (4)). In later 
studies, it was shown that treatment of preovulatory follicles with a solution of 
collagenase caused the follicle wall to dissociate when subjected to only slight tension 
(24). It became evident that the follicle wall becomes progressively weaker as the time of 
ovulation approaches. Furthermore, treatment of strips of the follicle wall with 
proteolytic enzymes mimicked the preovulatory degradation of follicular connective 
tissue. Several in vivo and in vitro studies demonstrated that a number of proteases can 
degrade the follicle wall, and it was firmly established that the collagenous layers of the 
theca externa and tunica albuginea at the apex of a follicle must be degraded before a 
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follicle can rupture (14). Subsequent efforts to measure proteolytic enzymes and their 
activity in the ovary were not successful until the 1980s. The recent studies on proteolysis 
during the periovulatory period are discussed later in the section 2.4. 
2.1.4 Ovulation as an inflammatory reaction 
Ovulation and inflammation are dynamic processes. Vasodilation, hyperemia, 
migration of white blood cells and fibroblasts, an increase in proinflammatory mediators, 
and activation of proteolytic enzymes can occur simultaneously; some follow one another 
in close sequence. 
The ovulatory LH surge causes measurable changes in the ovarian vasculature. 
Within a few minutes after gonadotropin stimulation, there is a significant increase in 
ovarian blood flow (25). Along with vasodilatation, there is an increase in vascular 
permeability in the follicles (26). These vascular changes cause the follicle to become 
edematous, and it remains such through the time of follicle rupture (27). Near the time of 
ovulation, because of the changes in the vascular system, erythrocytes permeate the walls 
of the vessels and form small hemorrhages in the interstitial spaces of the follicle (14). 
Thus, LH induces ovarian hyperemia, vasodilation, edema, and even hemorrhages in 
ovulatory follicles. In rabbits, 10 hours after mating, there is a conspicuous accumulation 
of basophils, other granulocytes, macrophages and thrombocytes in ovulating follicles 
(28). 
Similar to inflammatory and immune processes, during ovulation there was 
degranulation of mast cell histamine (29) and a decrease in the plasma bradykinin 
precursor kininogen (30). Both histamine and bradykinin induced ovulation in vitro in 
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perfusion systems (30, 31). However, antagonists of HI and H2 histamine receptors 
failed to inhibit ovulation in vivo (32, 33). The importance of histamine in ovulation has 
not been firmly established. The main question is whether histamine is a causative agent 
in the mechanism of ovulation or whether high levels of histamine result from the events 
that take place during the ovulatory process. Bradykinin is believed to promote ovulation 
by being responsible, at least in part, for the well known increase in prostaglandin 
production in periovulatory follicle (31, 34). 
Parallel to the events described above, theca cells and fibroblasts migrate into the 
granulosa cell layer (14). De-Asua describes fibroblasts as exhibiting either of "two 
extreme physiological states: quiescence or active proliferation" (35). Transition to the 
proliferating state can be regulated by numerous factors including prostaglandins. 
Prostaglandins can mediate the later stages of the inflammatory process by promoting 
fibroblast proliferation (35). The latter can also be induced by proteases that stimulate as 
much as a 7-fold increase in the frequency of mitosis in fibroblasts (36). Transformed 
fibroblasts themselves are a common source of prostaglandins and proteolytic enzymes 
like plasminogen activators. 
The resemblance of ovulation to an acute inflammatory process was further 
reinforced by findings showing that anti-inflammatory drugs can suppress ovulation (37, 
38). It became clear that in the mature ovarian follicle the ovulatory gonadotropin surge 
induces an elevation in prostaglandin synthesis that is necessary for ovulation to occur 
(39-41). These, and many other studies discussed in detail in the next chapter, depict 
ovulation as an acute, strictly controlled inflammation-like process with induction of 
proteolytic and collagenolytic activities. 
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2.2 Prostaglandins and Ovulation 
Prostaglandins (PGs) are bioactive eicosanoid lipid messengers that act as 
autocrine and paracrine agents. PGs stimulate a wide range of physiological responses in 
the cardiovascular, reproductive, urinary, respiratory and gastrointestinal systems. 
Commonly associated with inflammatory reactions, PGs can form during immune 
reactions and hormonal responses. Typical actions of PGs include the relaxation and 
contraction of various types of smooth muscle. PGs also modulate neuronal activity by 
either inhibiting or stimulating neurotransmitter release, sensitizing sensory fibers to 
noxious stimuli or inducing central actions such as fever generation and sleep induction. 
PGs also regulate secretion and motility in the gastrointestinal tract as well as transport of 
ions and water in the kidney. PGs are involved in apoptosis, cell differentiation and 
oncogenesis. PGs also regulate the activity of blood platelets and are involved in vascular 
homeostasis and hemostasis. 
2.2.1 Prostaglandin synthesis and catabolism 
Unlike many other biologically active substances, PGs are formed immediately 
prior to release and are not stored in the body. After biosynthesis, PGs are transported out 
of the cell by a PG transporter (42), where they exert their biological function through the 
G-protein coupled receptors (43). The inactivation of PGs takes place in the vascular 
beds; the lung is the primary site in metabolizing PGs (44). In the pulmonary circulation, 
the PGs are enzymatically converted to inactive 15-keto metabolites, and then further 
catabolized by p and TO oxidation. Polar catabolites are excreted in the urine and bile. 
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PGs are synthesized de novo from membrane-released arachidonic acid (AA) in 
response to almost any type of environmental condition that affect the plasma membrane 
(45). The biosynthesis of PGs can be divided into three phases: 1. release of the 
arachidonic acid from membrane phospholipids by a phospholipase; 2. conversion of 
arachidonic acid into an unstable intermediate PGH2 by cyclooxygenase enzymes; and 3. 
conversion of PGH2 into various biologically active PGs by a specific terminal synthase 
((46), Figure 2). 
PG biosynthesis is dependent upon the availability of free arachidonic acid. 
Intracellular levels of arachidonic acid are regulated by keeping it esterified until 
mobilized by phospholipases (PLA2). There are 4 major groups of PLA2. IB PLA2 is 
abundantly present in pancreatic juice (47). The IIA PLA2 (SPLA2) group consists of 10 
members, each with a highly conserved catalytic site and Ca -binding loop. SPLAi 
group members are stored in secretory granules of immune cells (46). IVA PLA2 (now 
called CPLA201) is activated by submicromolar Ca2+ and by phosphorylation; this enzyme 
shows a marked preference for AA over other fatty acids (48, 49). Lastly, iPLA2 activity 
is Ca2+ independent (50). Type IV cytosolic PLA2 is the key player in prostaglandin 
production within the periovulatory follicle (51). 
The next step in PG synthesis is catalyzed by the cyclooxygenase (COX) 
enzymes, also known as prostaglandin G/H synthases (52). These are heme-containing 
enzymes that catalyze two sequential enzymatic reactions: 1. the bis-oxygenation of AA 
leading to production of PGG2 (COX reaction) and 2. reduction of 15-hydroperoxide of 
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Figure 2. Synthesis of biologically active prostanoids. PLA2 -
phospholipase A2; COX = cyclooxigenase; PGIS = prostacyclin 
synthase; TXAS = thromboxane synthase; PGDS = PGD2 synthase; 
PGES = PGE2 synthase; PGFS = PGF2a synthase. 
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Three COX enzymes, COX-1, COX-2 and COX-3, are found in mammals. It is 
generally considered that COX-1 is constitutively expressed in a wide variety of cells and 
plays a housekeeping role (53). COX-2 is normally undetectable, but COX-2 expression 
can be induced by a variety of stimuli in certain tissues. A third COX enzyme, named 
COX-3, has recently been characterized in dogs, mice and rats, but the expression of a 
functional COX-3 in humans is still debated (54). 
Constitutive expression of COX-1 versus inducible expression of COX-2 implies 
that these enzymes have distinct roles in PG production in different phases of cell 
activation (55, 56). In general, COX-1 and COX-2 can be found on the lumenal surfaces 
of the ER and nuclear envelope (on both the inner and outer nuclear membranes) (57). 
COX-1 dependent PG production is an immediate response, which occurs within several 
minutes following a rise in cytoplasmic Ca2+ levels. The delayed PG production over 
hours after proinflammatory stimuli is COX-2, but not COX-1, mediated, even when both 
enzymes are expressed in the same cells. Induction of the COX-2 enzyme occurs in 
response to various stimuli, and the transcriptional regulation of COX-2 significantly 
differs according to stimulus and cell type (58). Transcription factors that activate COX-2 
transcription include NF-KB, C/EBPp and C/EBP5, AP-1, ATF, CREB and USF-1. The 
induction of COX-2 is markedly down-regulated by anti-inflammatory glucocorticoids 
(59). 
Inhibition of COX enzyme activity inevitably decreases PG production. In 1971, 
John Vane demonstrated that non-steroidal anti-inflammatory drugs (NSAIDs) inhibit PG 
synthesis (60). Later studies demonstrated that COX enzymes are the primary target of 
NSAIDs, including aspirin, indomethacin, ibuprofen, celecoxib and rofecoxib (61-64). 
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There is considerable variation in the relative potencies of NSAIDs to suppress 
prostaglandin biosynthesis. Aspirin (acetylsalicylic acid) is a weak inhibitor. Ibuprofen is 
a more potent inhibitor than aspirin but is less effective than indomethacin (61). Because 
NSAIDs act directly at the COX enzyme to reduce PGH2 synthesis, they rapidly became 
the drugs of choice to determine the role of PGs in biological processes including 
ovulation. The details of COX-2 regulation and PG synthesis in ovary are discussed in 
section 2.2.2. 
Bioactive PGE2 is synthesized from PGH2 by specific terminal synthases. In 
1999, a member of MAPEG (membrane associated proteins involved in eicosanoid and 
glutathione metabolism) superfamily was discovered to have the ability to catalyze the 
conversion of PGH2 to PGE2 with strict substrate specificity (65). Following this report, 
orthologs (genes in different species that evolved from a common ancestral gene) of this 
protein were cloned from several animal species and shown to represent a membrane-
bound form of PGE2 synthase mPGES-1 (66, 67). Immediately after this discovery, 
several cytosolic forms of PGES (cPGES (68, 69)) and a second form of membrane-
associated PGES, termed mPGES-2 were identified (70). 
The catabolism of PGs is initiated by oxidation of the 15(S)-hydroxyl group 
catalyzed by 15-hydorxyprostaglandin dehydrogenases (15-PGDHs) (71). As the 
resulting 15-ketoprostaglandins possess markedly reduced biological activities, 15-
PGDHs are considered to be the primary biological inactivators of PGs and other 
eicosanoids (72). Type I 15-PGDH is aNAD+ dependent enzyme and is involved 
primarily in PG and eicosanoid metabolism (73) whereas type II uses both NADP+ and 
NAD+ as cofactors and has broader substrate specificity (74). Although the main 
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function of PGDH enzymes is the inactivation of PGs in lung vascular beds (44), recent 
studies suggest that 15-PGDH is expressed in combination with PG synthesis enzymes to 
fine-tune local PG levels in PG-sensitive tissues. 
2.2.2 Prostaglandin synthesis and catabolism in periovulatory follicles 
A potential relationship between prostaglandin biosynthesis and ovulation first 
emerged during early 1970s when indomethacin-dependent inhibition of ovulation was 
initially reported in rats and rabbits (37, 38). For more than 30 years, PGs have been 
considered key inflammatory mediators of the ovulatory process inspiring special interest 
in reproductive scientists regarding the regulation of PG synthesis (39-41). 
In monkey granulosa cells, CPLA2 mRNA expression and PLA2 activity were 
increased toward the end of the periovulatory period (51). A cPLA2-selective inhibitor 
decreased both PLA2 activity in monkey granulosa cell lysates and PGE2 accumulation in 
cultures of human granulosa-lutein cells. Both cPLA2 and SPLA2IIA were expressed by 
granulosa cells of rat periovulatory follicles; gonadotropin exposure increased ovarian 
PLA2 expression in a manner consistent with a role for these enzymes in periovulatory 
PG production (75-77). cPLA2 -/- mice produced small litters, and the pups usually did 
not survive (78). These data indicate that CPLA2 is the primary enzyme responsible for 
the gonadotropin-stimulated mobilization of arachidonic acid necessary for PG 
production by periovulatory follicle. 
COX enzymes are expressed in mammalian ovary and play a significant role in 
ovulation (52). Levels of COX-1 mRNA in monkey granulosa cells of large antral 
follicles did not change across the periovulatory period, and COX-1 protein was not 
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detected in the granulosa or theca cells of these same follicles (79). These data suggest 
that COX-1 is not a major source of PG in primate periovulatory follicles. In the same 
study, COX-2 mRNA levels increased 12 hours after hCG administration and COX-2 
protein was detectable in granulosa cells 24 hours after hCG, which was followed by 
>200 fold increase in follicular fluid PGE2 levels. COX-2 expression and PG production 
are regulated by several pathways in ovarian granulosa cells. A cAMP-response element 
has been found in the promoter region of the rat and human COX-2 genes, consistent 
with activation of COX-2 gene expression through the LH/hCG receptor (80, 81). Several 
in vivo and in vitro studies showed that direct activators of the cAMP dependent protein 
kinase A (PKA) including hCG, LH and FSH, are able to upregulate COX-2 expression 
in periovulatory granulosa cells in rat, cattle, mare, and non-human primates (79, 80, 82, 
83). This results in elevated PG levels in periovulatory follicles, with granulosa cells 
being the primary site of PG synthesis ((79, 84, 85) Figure 3). Other mediators can also 
modulate COX-2 expression or activity in granulosa cells. Interleukin-1 has been shown 
to stimulate COX-2 expression in dispersed cells from the rat ovary and human 
luteinizing granulosa cells in vitro (86, 87). These studies established the role of COX-2 
as the main COX isozyme responsible for PG synthesis in ovary. 
The indomethacin-dependent inhibition of ovulation was initially reported in rats 
and rabbits (37, 38) but was subsequently observed in numerous species, including pigs, 
sheep, and cows (reviewed in (39, 41)). When indomethacin was administered 
intravenously during the ovulatory process, the normally elevated levels of PGE2 and 
prostaglandin F2ot (PGF2a) declined significantly within 1 to 2 minutes (88). The ability 
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Figure 3. PGE2 levels in follicular 
fluid. Follicular fluid obtained from 
monkey follicles before (0 h) and 12, 
24, and 36 h after hCG 
administration was subjected to EIA 
for PGE2. Groups with different 
letters are different, p value < 0.05. 
Data are expressed as mean ± SEM; 
n = 4-7/group. Modified from Duffy 




follicular PGs was quickly favored as the underlying mechanism responsible for causing 
anovulation. Subsequent studies used COX-2 selective inhibitors to prevent ovulation 
instead of the nonselective inhibitor indomethacin. NS-398 (COX-2 selective inhibitor) 
reduced the synthesis of PGE2 in isolated LH stimulated rat periovulatory follicles 
incubated in vitro (89). The highest dose of NS-398 that was used in in vitro studies 
decreased the number of ovulation sites when injected subcutaneously 1 hour after hCG 
administration. In a similar study in cows, follicular fluid PGE2 concentrations were 
decreased in NS-398 treated follicles when compared to follicles treated with diluent, and 
nine out of the ten NS-398-injected animals failed to ovulate (90). TheNS-398-injected 
follicles developed morphological and endocrine characteristics resembling luteinized, 
unruptured follicles. In a random double-blinded study, women whose dominant follicle 
had reached 14-16 mm in diameter received 25 mg rofecoxib (COX-2 selective inhibitor) 
or placebo orally for 9 days (91). By ultrasound scanning, follicular rupture in the 
placebo group was seen within 36 hours of the LH peak while mean rupture day in the 
rofecoxib treated group was day 4 after LH surge. 
The relationship between PGs and ovulation was further strengthened by studies 
in which PGs were able to restore ovulation in indomethacin treated rats, pigs, and rabbits 
(92-94). In perfused rat ovary, PGE2 reversed the inhibition of ovulation by 
forskolin+indomethacin (95). In rhesus monkeys, on the day before or the day of the LH 
surge, intrafollicular injection of indomethacin at final concentration of 10~6 mol/1 or 10"5 
mol/1 prevented ovulatory stigmata formation and oocyte release in 4/8 animals ((96) 
Figure 4). In contrast, oocytes were not detected in the ruptured, luteinizing follicles from 
all three indomethacin+PGE2-injected monkeys Knockout studies in mice confirmed the 
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role of PGE2 in ovulation (97). COX-2-/- mice failed to increase intrafollicular PGE2 
levels and ovulate in response to PMSG-hCG stimulation. Gonadotropin stimulation and 
concurrent treatment with PGE2 resulted in ovulation of COX-2-/- mice comparable to 
that in wild type animals. These studies suggest that PGE2 may be important for 
successful ovulation in species like rat, mouse and monkey. 
Studies presented above have demonstrated the essential role played by 
gonadotropin-stimulated COX-2 in ovulation. Although gonadotropins upregulate PG 
production via stimulation of PG synthesis enzymes, the intrafollicular PG levels are 
fine-tuned by additional gonadotropin regulation of enzymes that are involved in 
catabolism of ovarian bioactive PGs. 
In female reproductive organs, the PGE2 synthesis enzyme mPGES-1 is highly 
expressed in granulosa cells of follicles, the same cell type in which COX-2 is expressed 
after stimulation with gonadotropins (98). Monkey granulosa cells expressed mPGES-1, 
-2 and cPGES mRNA (85). Only the expression of mPGES-1 mRNA and protein 
increased in response to hCG administration, peaking just before the expected time of 
ovulation, which suggests that mPGES-1 may be the primary PGES responsible for the 
increased follicular PGE2 levels necessary for primate ovulation. 
The PG catabolic enzyme NAD+ dependent 15-PGDH is expressed in 
periovulatory granulosa cells as detected by RT-PCR, western blotting, and 
immunohistochemistry (99, 100). In the non-human primate, PGDH expression and 
activity were high in early and mid periovulatory period (99). As a result, despite 
increased PG synthesis, there was no PGE2 accumulation in follicular fluid. However, 36 
hours after hCG administration, PGDH expression and activity in granulosa cells 
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Figure 4. Ovarian morphology and trapped oocytes after follicular injection (96). 
Follicles were injected with vehicle (A), 10"5 mol/1 indomethacin (B), or 10~5 mol/1 
indomethacin + PGE2 (C). Three days after follicle injection, the ovary was 
observed during laparoscopic surgery (A-C). Some ovaries were removed 3 days 
after follicle injection, and serial sections were stained with haemotoxylin and eosin 
(I). In A-C, the ovulatory stigmata is indicated by an arrow. Histological 
examination of ovarian sections (I) shows the presence of luteinizing granulosa cells 
(lgc) and stroma (st). Trapped oocytes (arrow) were observed within four out of 
eight indomethacin-injected follicles (I). The oocyte of the injected follicle is 
surrounded by luteinizing granulosa cells (lgc); the oocyte (asterisk) of a 
neighbouring secondary follicle surrounded by ovarian stroma (st) is also shown. 
Bar =100 urn. Modified from Duffy et al. ((96), by permission of Oxford University 
Press). 
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declined whereas COX-2 maintained high expression, which allowed for newly 
produced PGE2 to accumulate in follicular fluid. These data suggest that in non-human 
primates, PG catabolism and synthesis act in coordinated manner to delay PGE2 
elevation until just before expected time of ovulation when it acts to advance the oocyte 
release. 
The dramatically elevated intrafollicular PGE2 levels immediately before the 
expected time of ovulation and the ability of exogenous PGE2 to reverse the anovulatory 
effect of COX inhibitors indicate that PGE2 is the key ovulatory PG in several 
mammalian species. In this respect, it becomes essential to examine the expression and 
function of PGE2 receptors in periovulatory granulosa cells. 
2.3 PGE2 Receptors 
Most, if not all, tissues respond to PGs. The long list of PG actions include 
smooth muscle contraction and relaxation, autonomic neurotransmission, natriuresis, 
diuresis, inhibition of platelet adhesiveness and aggregation, redistribution of blood flow 
and many others (101). The same PGs may have qualitatively dissimilar effects upon 
different tissues. For example, the vasodilator effect of PGE2 on both arterial and venous 
vascular beds was one of the first recognized actions of PGE2 (102). However, PGE2 
does not uniformly relax smooth muscle and has been shown to constrict trachea, gastric 
fundus, and ileum (103). These differential effects of PGE2 provided important initial 
evidence for the existence of multiple PGE2 receptors. 
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The PGE2 receptors (EP receptors) are members of the G protein coupled family 
of receptors, each possessing seven hydrophobic, membrane-spanning a helices (104, 
105). The N-terminal segment of these receptors is on the extracellular face, and the C-
terminal segment is on the cytosolic face of the plasma membrane. These receptors 
transmit signals to intracellular targets via the intermediary action of guanine nucleotide-
binding proteins called G proteins (106). The binding of ligands to the extracellular 
domain of these receptors induces a conformational change that allows the cytosolic 
domain of the receptor to bind to and activate a G protein associated with the inner face 
of the plasma membrane (107). 
G proteins consist of three subunits, designated a, p, and y (107-109). They are 
frequently called heterotrimeric G proteins to distinguish them from other guanine 
nucleotide-binding proteins, such as the Ras proteins. The a subunit binds guanine 
nucleotides, which regulates G protein activity. In the resting state, a is bound to 
guanosine diphosphate (GDP) in a complex with (3 and y. Ligand binding induces a 
conformational change in the receptor, such that the cytosolic domain of the receptor 
interacts with the G protein and stimulates the release of bound GDP and its exchange for 
guanosine triphosphate (GTP). The activated GTP-bound a subunit then dissociates from 
P and y, which remain together and function as a Py complex. Both the active GTP-bound 
a subunit and the Py complex then interact with their targets to elicit intracellular 
responses. The activity of the a subunit is terminated by hydrolysis of the bound GTP, 
and the inactive a subunit (now with GDP bound) then re-associates with the Py complex, 
ready for the cycle to start anew. Mammalian genome encodes at least 20 different a 
subunits, 6 P subunits, and 12 y subunits. Receptors that are coupled with Gas stimulate 
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adenylyl cyclase to increase cAMP (109). God coupled receptors inhibit adenylyl cyclase 
and inhibit cAMP production, and Gaq stimulates phospholipase C (PLC) to generate IP3 
and diacylglycerol as second messengers and increases intracellular Ca2+ (110). 
The actions of PGE2 are mediated by four different G-protein coupled receptors: 
EP1, EP2, EP3 and EP4 (Figure 5). The EP subtypes differ in tissue distribution, ligand-
binding affinity, coupling to intracellular signaling pathways and functions. 
2.3.1 TheEPl receptor 
The human EP1 receptor cDNA encodes a 402-amino acid polypeptide with a 
predicted molecular mass of 41,858 kDa (111). A splice variant of EP1 (rEPl-v) was 
cloned from a rat uterus cDNA library (112). The open reading frame of rEPl-v carries a 
specific change of 49 amino acids from the middle of transmembrane segment VI to the 
COOH terminus; it possesses a transmembrane segment VH-like structure lacking an 
intracellular COOH-terminal tail. The rEPl-v receptor retained the ligand binding 
activity with affinity and specificity similar to the rEPl receptor but lost the coupling of 
signal transduction systems by itself. The generation of second messengers and activation 
of signal transduction pathways via EP receptors can be studied using receptor selective 
agonists and antagonists. 
There is no reported example of a highly selective EP1 agonist. Three compounds 
that have proven useful are sulprostone, 17-phenyl-trinor PGE2 and iloprost (103, 113, 

























Figure 5. EP receptors. All EP receptors are G protein coupled 
receptors. Each EP receptor couples to a single G protein. 
Each isoform of EP3 couples to a single G protein (Gas, Gai, 
or Gaq) as determined by the C-terminal sequence of the 
receptor protein. 
activates EP1 and EP3 receptors. Uoprost is more selective for EP1 receptors over EP2 
and EP3, but it is also a highly potent PGI2 receptor (IP receptor) agonist, being at least 
as potent as PGI2 itself. There are 2 compounds known to posses specific EP1 antagonist 
activity: SC-19220 and AH6809 (105). The utility of these antagonists is limited because 
SC-19220 has low efficacy and is poorly soluble in water whereas AH6809 is an 
effective antagonist of both EP1 and EP2 receptors. A significant stimulus for the 
development of pharmacologically and clinically active EP1 receptor antagonists derives 
from evidence that the EP1 receptor plays an important role in PG-mediated pain (115) 
and that EP1 receptor antagonists have analgesic properties (116). 
EP1 receptor is involved in Ca2+mobilization (111, 117). PGE2 caused an 
increase in intracellular Ca2+ concentration ([Ca2+]i) in cells expressing the recombinant 
murine EP1 receptor (117). It was suggested that EP1 receptors are coupled to Gaq as the 
activation of these receptors by receptor specific agonists increased [Ca2+|i, which was 
accompanied by modest increases in IP3 generation (117). In another study, PGE2 and 
the EP1 selective agonist 17-phenyl-trinor PGE2 induced fibronectin expression in rat 
osteoblasts (118). Use of EP1 receptor antisense oligonucleotides, Ca2+ chelaters or PLC 
inhibitors attenuated the PGE2-induced fibronectin expression, implying that EP1 
receptors are Gaq coupled. In cultured human myometrial cells, PGE2 increased [Ca2+]i 
via a pertussis toxin-sensitive pathway, without PLC activation. This [Ca2+]i increase 
occurred after an inverse dose-related delay and could be inhibited by either the selective 
EP1 antagonist AH6809 or calcium channel blockers (119). In Chinese hamster ovary 
cells expressing EP1 receptors, a receptor selective agonist induced an elevation in 
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[Ca2+]i that was PLC independent (120). The data from the above described and other 
studies suggest that EP1 regulates [Ca2+]i via an unidentified G protein. 
The EP1 receptor was originally described as a smooth muscle constrictor (121). 
EP1 receptors do not appear to have wide tissue distribution, being most evident in 
smooth muscle cells of trachea, the gastrointestinal tract, the uterus, and the bladder (105, 
122). Watanabe et al. examined colon carcinogenesis in EP1-/- mice (123). The number 
of azoxymethane (potent carcinogen)-induced aberrant foci in the colons of EP-/- mice 
decreased by -40% relative to that for wild type mice. An EP1 selective antagonist 
reduced the development of aberrant foci in wild-type mice by 30% and the number of 
intestinal polyps by ~40%>. In mice, EP1 expression was detected in kidney collecting 
ducts and in lung (124). In the rabbit collecting duct, activation of the EP1 receptors 
inhibited Na+ and water reabsorption via a Ca2+ coupled mechanism (125). EP1 
mediated contractility was detected in human non-pregnant myometrium (126). In the 
human ovary, the mRNA for EP1 was present in granulosa-lutein cells (127). The 
exposure of granulosa-lutein cells to PGE2 transiently raised [Ca2+]i levels, which could 
be prevented by EP1 antagonist AH6809. High resolution immunostaining for EP1 
revealed their presence in the nuclear envelope of isolated endothelial cells and in situ in 
brain endothelial cells and neurons (128). Stimulation of these nuclear receptors 
modulated nuclear calcium and gene transcription. 
Despite numerous studies conducted in various species and tissues, the signaling 
pathway utilized by EP1 receptors is still unclear. The role of EP1 has been most 
extensively studied in the context of smooth muscle contraction and natriuresis. 
However, very little is known about EP1 receptor expression, function and regulation in 
reproductive systems, including the periovulatory follicle. 
2.3.2 The EP2 receptor 
The human EP2 receptor cDNA encodes a 358-amino acid polypeptide (129, 
130). Mutagenesis studies have demonstrated that the extracellular loop regions of the 
EP2 receptor are critical determinants of receptor function. Introduction of point 
mutations (131) or creation of receptor chimeras with the EP4 receptor in certain 
extracellular regions (132) resulted in a loss of receptor binding and signal transduction. 
A single point mutation in the seventh transmembrane domain of the EP2 receptor caused 
a selective gain of function of the receptor for prostacyclin analogs (133). Taken together, 
these data suggest that both the extracellular sequences and the transmembrane regions 
are important for receptor ligand interactions. 
EP2 receptors are selectively activated by butaprost and inhibited by AH6809 
(133-135). Activation of Gas coupled EP2 receptors by PGE2 or selective agonists leads 
to activation of adenylyl cyclase and increase in cAMP production (105, 136). Evidence 
of an association between EP2 receptors and cAMP generation has been obtained for 
enterocytes and corneal endothelial cells (137, 138). PGE2 and butaprost increased the 
cAMP level in a concentration-dependent manner in the Chinese hamster ovary cells 
stably expressing EP2 receptor (139). 
EP2 is considered a relaxant receptor as it induces smooth muscle relaxation 
(135). The precise distribution of the EP2 receptor has been only partially characterized 
using Northern blot analysis of mRNA distribution. Such studies reveal a major mRNA 
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species of ~3.1 kb that is most abundant in the uterus, lung, and spleen; low levels of 
expression were measured in the kidney (130, 134, 139, 140). Lipopolysaccharide (LPS), 
an endotoxin of the outer membrane of Gram-negative bacteria, upregulated EP2 
expression in a macrophage cell line; this augmentation was completely inhibited by the 
simultaneous administration of IFN-y (141). In mouse uterus, EP2 mRNA, which was 
hardly detectable before induction of pseudopregnancy, peaked at day 5 of pregnancy and 
disappeared quickly thereafter suggesting that EP2 may be involved in the implantation 
process (142). 
In the mouse ovary, EP2 mRNA was present in both mural and cumulus 
granulosa cells 3 hours after hCG injection (143). In human granulosa-lutein cells, EP2 
receptor mRNA was detected by RT-PCR (127), and treatment with the EP2 selective 
agonist butaprost stimulated both cAMP formation and progesterone production. In 
another study, the transcript for the EP2 receptor was localized in the corpus luteum of 
the mouse ovary by in situ hybridization, and EP2 protein was expressed in human 
corpus luteum as detected by immunohistochemistry (144). 
The role of EP2 receptors in vascular responsiveness and blood pressure was 
elucidated by knockout studies. Bolus administration of PGE2 produced a transient 
hypotensive effect in wild-type mice, whereas it elicited a transient hypertensive response 
in EP2-/- mice, suggesting that the vasodilatory action of PGE2 was mediated by EP2 
(145). While baseline blood pressure in EP2-/- mice was slightly higher only in females 
compared with that of in wild-type females, marked elevation of systolic blood pressure 
was observed in EP2-/- mice after they were fed a high-salt diet. These results show that 
unopposed vasoconstriction via the EP1 and/or EP3 receptor in EP2-/- mice could 
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contribute to the observed hypertension, particularly when PGE2 production was 
increased with a high-salt diet. 
The studies in knockout mice elucidated the role of EP2 in reproductive 
physiology. Female EP2 -/- mice have reduced litter size (145-147). Hizaki et al. 
analyzed the mechanism of this reproductive failure in detail (146). The average number 
of embryos at day 19 of pregnancy in EP2-/- mice was 1.5, whereas that in wild-type 
mice was 7.1. There was no abnormality of implantation in EP2-/- mice when examined 
by intrauterine transfer of wild-type blastocysts. However, EP2-/- females had impaired 
ovulation. In wild-type females, PGE2, FSH and dibutyryl cAMP each elicited cumulus 
expansion of in vitro. However, in EP2-/- females, only PGE2 failed to elicit cumulus 
expansion. Moreover, abortive cumulus expansion was found in EP2-/- females in vivo. 
These results demonstrated that PGE2 via the EP2 contributes to cumulus expansion and 
that this contribution is indispensable for successful ovulation and fertilization. 
Although above-mentioned studies demonstrate the importance of EP2 receptors 
for the mouse fertility, very little is known about EP2 receptor expression and regulation 
in periovulatory granulosa cells and its role in primate ovulation. 
2.3.3 The EP3 receptor 
EP3 receptor is unique in that multiple splice variants defined by unique COOH-
terminal cytoplasmic tails exist in humans, rats, rabbits, mice, and cows (130, 148-151). 
During the cloning of EP3 receptor from a bovine adrenal gland cDNA library, it was 
found that the EP3 mRNA undergoes alternative splicing in this tissue to produce at least 
four EP3 isoforms (EP3A, EP3B, EP3C, and EP3D (151)). The deduced amino acid 
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sequences of these isoforms are identical from the amino terminus to the tenth 
intracellular amino acids after the seventh transmembrane domain, but differ thereafter. 
The four isoforms showed almost identical ligand-binding specificities. Yet these 
isoforms couple to different G-proteins to regulate different signaling pathways. The 
bovine EP3A receptor couples to God and induces the inhibition of adenylyl cyclase, 
whereas the EP3B and EP3C receptors are coupled to Gas and act to increase levels of 
cAMP. The EP3D receptor couples to Gaq, in addition to God and Gas, and can evoke a 
pertussis toxin-insensitive response (151). 
At least three EP3 isoforms (EP3a, EP3|3, and EP3y) are present in the mouse 
(150), and homologous splice variants are found in rabbit and human (149, 152). These 
isoforms show alternative splicing at the position identical with that found in the bovine 
variants. Among the mouse isoforms, EP3a andEP3p couple to the same G-protein, Gai, 
and inhibit adenylyl cyclase but are different in their ligand binding affinities and 
agonist-induced desensitization (110, 153). The third isoform, EP3y can couple to Gas in 
addition to Gai and, at higher agonist concentrations, tends to stimulate adenylyl cyclase 
(150). The human EP3 gene formed nine distinct mRNAs encoding eight EP3 isoforms: 
EP3-Ia, EP3-Ib, EP3-II, EP3-III, EP3-IV, EP3-V, EP3-VI, EP3e, EP3f (154). All the EP3 
splice variants bind PGE2 and the EP3 agonists with similar affinity (155). Signaling 
experiments revealed that an EP3 agonist not only inhibited forskolin-induced cAMP 
concentrations but also activated mitogen-activated protein kinase in Chinese hamster 
ovary cells stably expressing human EP3-V and EP3-VI. These responses were abolished 
by treatment with pertussis toxin. In addition, the EP3 agonist increased cAMP 
concentrations in EP3VI-expressing cells but was ineffective in EP3V-expressing cells 
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(156). Four human EP3 isoforms (EP3-I - EP3-IV) inhibited adenylyl cyclase in an 
agonist dependent manner when over-expressed in Chinese hamster ovary cells (157). 
The EP3 receptor is expressed in many tissues including kidney, uterus, adrenal 
gland, stomach, with Northern analysis showing major mRNA species at -2.4 and -7.0 
kb (149, 158-160). EP3 receptor levels are relatively high in mouse, rabbit, and human 
kidney, where EP3 is expressed in the tubular epithelium, the thick ascending limb, and 
the cortical collecting ducts in the outer medulla (124, 161, 162). In addition, high 
expression of EP3 mRNA was found in neurons of the myenteric ganglia (135). In 
hypothalamus, EP3 mRNA is expressed in the neurons surrounding the organum 
vasculosa lamina terminalis (163). 
The EP3 receptor is known as an inhibitory receptor that generally acts as a 
constrictor of smooth muscle by decreasing cAMP (105). The significance of EP3 
receptor activation to systemic physiology has been significantly advanced by the 
availability of mice with targeted disruption of this gene (164, 165). EP3-/- mice exhibit 
an impaired febrile (fever generating) response to PGE2, suggesting that EP3 receptor 
antagonists could be effective antipyretic (fever reducing) agents. LPS injected 
intravenously induced a fever in wild type mice, whereas it failed to induce a fever in 
EP3-/- mice (165). It was also confirmed that EP3-/- mice show a normal febrile response 
when subjected to a restraint stress, suggesting that EP3 is essential in the febrile 
response to LPS while the efferent pathway to fever generation is EP3 independent. Acid-
induced mucosal injury was markedly augmented in EP3-/- mice compared with that in 
wild type mice and was similar to that in wild type mice pretreated with indomethacin, 
suggesting that PGE2 plays a major role via the EP3 receptor in acid induced bicarbonate 
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secretion (166). Despite relatively high levels of EP3 receptor in kidney, mice with 
targeted disruption of this receptor display only a subtle alteration in urine concentrating 
ability (164). In EP3-/- mice, PGE2 failed to induce degranulation of mast cells whereas 
in wild-type animals PGE2-induced degranulation was preceded by inhibition of adenylyl 
cyclase and increased [Ca2+]i, indicating that at least two EP3 isoforms are responsible 
for this PGE2 effect (167). 
Despite being a widespread receptor involved in many physiological responses, 
EP3 is probably the least studied PGE2 receptor in primates in general and in primate 
reproductive tract in particular. To date, there is no information about EP3 receptor 
expression and function in primate ovulation. 
2.3.4 The EP4 receptor 
The human EP4 receptor cDNA encodes a 488-amino acid polypeptide with a 
predicted molecular mass of ~53 kDa (129). The EP4 nomenclature is confusing as in 
literature dated before 1995 this receptor was referred to as the EP2 receptor (168). Like 
the EP2 receptor, the EP4 is a relaxant receptor and signals through Gas and increased 
cAMP (129, 130). Structurally, the EP4 receptor has a much longer COOH-terminal 
sequence than the EP2 receptor and has been shown to undergo short-term agonist-
induced desensitization, which is absent in the EP2 receptor (169, 170). EP4 receptors 
may be pharmacologically distinguished from the EP1 and EP3 receptors by their 
insensitivity to sulprostone and from EP2 receptors by their insensitivity to butaprost and 
relatively selective activation by PGE1-OH (134, 171). Furthermore, [3H]PGE2 binds to 
the EP4 receptor with at least 10-fold higher affinity than the EP2 receptor. In addition to 
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the human EP4, receptors for mouse, rat, rabbit, and cow have been cloned (129, 134, 
168, 172-174). 
EP4 is widely distributed throughout the body, and its mRNA is expressed in 
almost all mouse tissues examined (174). Its major species of ~3.8kb was detected by 
Northern analysis in rabbit thymus, ileum, lung, spleen, adrenal gland, and kidney (173). 
It was also found in neurons of the hypothalamus and lower brain stem and in neurons of 
the dorsal root ganglion (124, 175). In situ hybridization studies of PGE2 receptors in the 
kidney have revealed that the EP4 receptor is expressed in the glomerulus (124, 161, 162, 
173). Expression of the EP4 receptor has also been described in venous and arterial beds 
of the piglet (105). EP4 mRNA is highly expressed in the gland of the gastric antrum, 
indicating that this subtype is involved in PGE2-mediated mucus secretion (176). In 
addition, the transcript of this receptor is present in intestinal epithelial cells, especially 
those in the upper part of the villi (177). In situ hybridization was also used to examine 
the cellular localization of mRNA for EP receptor subtypes in the mouse uterus (142). 
The abundance and localization of mRNA for EP4 were found to change considerably in 
mice undergoing pseudopregnancy. EP4 mRNA expression sharply increased on day 3 of 
pseudopregnancy and was maintained at a high level after day 5. Its expression was 
limited to luminal epithelial cells at day 0 but was also expressed in endometrial stromal 
cells and the glandular epithelium after induction. 
In human ovarian granulosa-luteal cells, EP4 receptor mRNA levels were low or 
non-detectable in vivo, but the pro-inflammatory cytokine IL-lp stimulated expression of 
EP4 transcripts in concentration- and time-dependent manner (144). In mouse, EP4 
mRNA was present in mural and cumulus granulosa cells 3 and 9 hours after hCG 
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administration (143). In the oviduct, the expression of EP4 was localized to epithelial 
cells. In the rat ovary, most dense immunostaining for EP4 receptor was noticed in 
proliferating granulosa cells of the secondary follicles while those of the primordial and 
primary follicles were not stained (178). 
Similar to their vast distribution in various tissues, a variety of functions is 
attributed to EP4 receptors. Although its precise function in kidney glomeruli is yet 
uncharacterized, EP4 might contribute to regulation of the renal microcirculation as well 
as renin release (161, 162, 173). Vasodilator effect of EP4 activation was described in 
piglets (105). Other roles for the EP4 receptor in controlling blood pressure have been 
suggested, including the ability to stimulate aldosterone release from zona glomerulosa 
cells (179). Because EP4 via Gas is coupled to an increases in cAMP, and PGE2 
stimulates chloride secretion and inhibits NaCl absorption in the intestine through the 
production of cAMP, it has been suggested that EP4 is involved in these processes and 
consequently in PGE2-induced diarrhea (176). 
A study using various PG analogs suggested that EP4 is present in the ductus 
arteriosus and participates in the dilation of this vessel (180). The presence of the EP4 
receptor in ductus was confirmed by in situ hybridization of its mRNA in the mouse (181, 
182). The disruption of the EP4 receptor gene resulted in the death of most homozygous 
EP4-/- neonates within 3 days after birth, due to marked pulmonary congestion and heart 
failure (181,182). 
In co-cultures of primary osteoblasts and bone marrow cells that contain 
osteoclast precursors, EP4 agonists induced osteoclast formation (183). Although EP4 
deficient mice did not show gross skeletal abnormalities, PGE2-induced osteoclast 
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formation was impaired in cultured osteoblasts from the EP4-deficient mice and 
osteoclast precursors from the spleens of wild type mice. In mouse calvaria cultures, an 
EP4 agonist induced cAMP production and the expression of osteoclast differentiation 
factor mRNA in osteoblastic cells (184). In calvaria cultured from EP4 knockout mice, 
there was marked reduction in bone resorption in response to PGE2. In the same mice, 
EP4 agonist failed to induce bone resorption. These findings suggest that PGE2 
stimulates bone resorption by a mechanism involving cAMP and osteoclast 
differentiation factor, both of which are mediated mainly by EP4. 
Very little is known about EP4 receptor function in the reproductive tract. PGE2 
has been reported to cause a phenotypic change in decidualization of the endometrium 
via elevation of cAMP levels (135). This may be mediated by EP4 receptors in stromal 
cells of the endometrium (142). In the rat ovary, EP4 analog injection induced follicle 
growth with morphological characteristics similar to that induced by pregnant mare 
serum gonadotropin (PMSG) used to stimulate follicle development (178). The data 
suggest that signaling through EP4 may be important for follicle growth and maturation. 
Molecular cloning of the PGE2 receptors and elucidation of properties such as 
ligand binding, signal transduction, and distribution have been pivotal in our 
understanding of PG physiology. The importance of each PGE2 receptor can also be 
assessed by the use of knockout mice deficient in each receptor in various physiological 
and pathophysiological settings. Although extensively studied in species like rabbit, 
mouse, and rat, very little is known about the distribution and function of EP receptors in 
primates. The fact that PGE2 plays an important role in such a crucial function as 
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ovulation makes it especially important to elucidate the location and function of each and 
every EP receptor in the primate ovary. 
2.4 Proteolysis in Ovulation 
The extracellular matrix (ECM) provides a structural scaffold for tissue support 
and forms a barrier between tissue compartments. Many physiological and pathological 
processes including follicular development, ovulation, embryo implantation, 
angiogenesis, wound healing, bone remodeling and tumor invasion require a regulated 
turnover of ECM components (185-188). The ECM influences basic cellular processes 
such as proliferation, differentiation, migration and adhesion and is, therefore, 
fundamental to normal development (187, 189). Due to the complex composition of the 
ECM, different proteases with different substrate specificities are required for ECM 
remodeling and degradation. As physiological proteolysis often must be spatially 
restricted and targeted, the maintenance of health requires strict control of proteolytic 
enzymes and their activity. Fine-tuning of proteolytic activity is achieved by establishing 
balance between the level of proteases and their inhibitors (190). Ovulation is a vivid 
example of a physiological event that requires rigorous regulation of spatially and 
temporally restricted proteolysis. 
The ovarian follicle is the unit in which an oocyte matures and from which the 
oocyte is extruded for subsequent fertilization. Each follicle destined for ovulation must 
complete the development and differentiation of its components: oocyte, granulosa cells, 
and theca cells. Concurrently, it requires extensive changes in the extracellular 
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environment, including angiogenesis and rapid expansion of the follicular size (190,191). 
The climactic event of this process is follicle rupture, which occurs at a precise area on 
the ovarian surface (the apex), followed by the extrusion of a mature oocyte. 
Many cell layers are present at the follicle apex (Figure 6). The ovarian surface 
epithelium that comprises the outmost layer of the ovarian wall lines tunica albuginea 
(192, 193). The layer below the tunica albuginea contains theca externa and is a dense 
collagenous mesh work, which contributes most of the tensile strength of the follicle wall. 
The theca interna is a well-vascularized layer between theca externa and the follicular 
basal lamina. The follicular side of the basal lamina is lined with mural granulosa cells. 
The periovulatory follicle contains three distinct layers of connective tissue (13, 26). 
Collagen type IV predominates in the outermost epithelial layer. The tunica albuginea and 
theca externa layer consist primarily of collagen types I and III, whose fibrils provide 
structural support and tensile strength to the follicle wall (194, 195). The basal lamina, 
which separates the vascular theca and avascular granulosa layers, is composed mainly of 
collagen type IV, laminin, fibronectin, and proteoglycan (194, 196). The breakdown of 
multiple layers at the follicle apex during ovulation requires extensive proteolysis to 
degrade these extracellular matrix proteins. 
In the ovulatory process, proteolysis has been postulated to degrade the apical 
follicular connective tissue, reducing the structural integrity of the follicular wall and 
thereby facilitating oocyte release (4). After a long period of conflicting data and 
opinions, the overwhelming consensus is that there is an increase in collagenase and 
gelatinase activity within the periovulatory follicle before ovulation (197-201). In species 
such as rat, mouse, ovine, and human, the increase in proteolytic activity was 
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Figure 6. Cell layers and extracellular matrix 
proteins present at the follicle apex. 
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demonstrated in intact ovaries, follicles, follicular fluid, conditioned medium from 
cultured follicles, isolated granulosa cells, and theca cells (202-207). Increased 
proteolytic activity was dependent on an LH stimulus (198, 208). There was a 4- to 5-fold 
increase in gelatinase and collagenase activity after LH/hCG stimulation in the rat, which 
was blocked by inhibiting the endogenous LH surge with Nembutal (198, 200, 208, 209). 
In the human, gelatinolytic activity in follicular fluid increased 4-fold between menstrual 
cycle day 5 and 13 (205). A similar increase in gelatinolytic activity was observed in 
ovine follicles and follicular fluid before ovulation (210, 211). The induction of 
proteolytic activity by gonadotropins in many mammalian species indicates that 
proteolysis might be a necessary periovulatory event. 
A large number of proteases present in the ovary have been suggested to be 
involved in the proteolysis of ECM which contributes to ovulation (191,211,212). These 
can be classified into several protease families based on their distinct domain structures: 
1. Matrix metalloproteases (MMPs) are a large family of zinc containing enzymes 
with highly conserved functional domains (213-215). 
2. Serine proteases of plasminogen activator/plasmin system (216, 217). 
3. ADAMTSs (a desintegrin and metalloprotease domain with thrombospondin 
motifs) are large family of soluble glycoproteins with important roles in cell-to-cell 
adhesion and ECM proteolysis (218). 
4. Lysosomal cathepsin-L is a protease, which is a downstream target of the 
progesterone receptor (219,220). 
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2.4.1 MMPs and TIMPs 
MMPs belong to a metzincin family comprised of 25 structurally related members 
(221-224) that can be divided into four broad classes: the collagenases, gelatinases, 
stromelysins, and membrane type enzymes (225). These proteases exhibit numerous 
structural and functional similarities. Common features of the MMP family include: 1) 
the presence of zinc in the active site of the catalytic domain, 2) synthesis of the MMPs as 
preproenzymes that are secreted in an inactive form, 3) activation of the latent zymogen 
in the extracellular space, 4) recognition and cleavage of the ECM by the catalytic domain 
of the enzyme, and 5) inhibition of enzyme action by both serum-born and tissue-derived 
metalloprotease inhibitors in the extracellular environment. 
MMP synthesis and activation are critical points of regulation of ECM 
homeostasis (226). The regulation of MMP synthesis can be both tissue- and MMP-
specific. MMPs are synthesized as inactive pro-enzymes (pro-MMPs) and secreted into 
the extracellular space. Activation of the pro-MMPs in the extracellular space occurs via 
proteases, including other MMPs, serine proteases of PA/plasmin system, cysteine 
proteases, as well as by nonproteolytic agents such as reactive oxygen species, sulfhydryl 
reactive agents, and denaturants. The PA/plasmin system has been proposed to activate 
MMPs at the cell surface. Thus, the activation of MMPs can be regulated by a balance 
between serine proteases and their inhibitors (222, 223). However, MMPs that are 
resistant to serine protease activation, such as MMP-2, are activated via a novel 
mechanism involving the MT-MMPs and tissue inhibitor of metalloprotease-2 (223). 
In addition to the regulation of MMP synthesis and activation, MMP activity in 
the extracellular environment is rigorously controlled by MMP inhibitors. Two major 
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classes of MMP inhibitors are generally distinguished, serum born and tissue derived 
(227, 228). The serum born inhibitors include the a2-, al-macroglobulins, al-inhibitor-3, 
pregnancy zone protein and the ovomacroglobulines (e.g., ovostatin). This class of 
inhibitors is a major regulator of collagenolysis in serum and tissue fluids (226). Tissue 
inhibitors of metalloproteases, or TIMPs, are locally produced and specifically inhibit 
MMPs. In 1975, two separate investigators reported inhibition of collagenolytic activity 
by a small molecular weight protein (229, 230). This secreted 29 kDa protein, now called 
TIMP-1, was shown to bind and inhibit the active form of MMPs on a 1:1 stoichiometric 
basis (231). The N-terminal domain of TIMP binds to and inactivates the catalytic 
domain of the MMP. In addition, TIMP blocks the substrate-binding groove of the MMP. 
Following the discovery of TIMP-1, three other MMP inhibitors have been identified 
including TIMP-2, glycosylated inhibitor TIMP-3, and TIMP-4 (227). There is evidence 
indicating that TIMPs, in addition to their ability to regulate MMP activity, regulate 
many aspects of cell physiology, including cell growth, angiogenesis and steroidogenesis 
(232). 
2.4.2 MMPs and TIMPs in ovulation 
As a major group of ECM-degrading enzymes, MMPs and TIMPs have been 
implicated in local control of ovulation (190, 191, 225). There is a body of morphological 
and biochemical studies suggesting an important role for the MMPs in ECM degradation 
associated with follicle rupture. Regulation of the expression of MMPs and TIMPs by 
ovulatory gonadotropins is one of the indicators of the involvement of these proteases in 
the process of ovulation. In the rodent ovary, mRNA expression of MMP-1, MMP-2, 
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MMP-9 and MMP-13 all increased after the endogenous LH surge or administration of 
hCG to immature PMSG-primed animals (233-235). In the bovine follicle, the expression 
of mRNA for MT1-MMP and TIMP-2 was elevated at 6 and 24 hours after the 
gonadotropin surge, respectively (236). In the primate, hCG administration increased 
granulosa cell expression of mRNA for MMP-1, MMP-2, and MMP-7 within 12 h, 
whereas an increase in MMP-9 mRNA occurred at 36 hours after hCG (237). These data 
show that the expression of collagenolytic MMPs increases as the ovulation approaches. 
The crucial role of the MMPs in follicle rupture was demonstrated by experiments 
in which ovulation was blocked by exogenous chemical MMP inhibitors both in vitro and 
in vivo, as well as by antibodies against individual MMPs (208, 238-240). In the perfused 
rat ovary, the release of oocytes was blocked or inhibited by the metalloprotease 
inhibitors phenanthroline or SC 40827 (239). When injected into the antral cavity of 
sheep follicles, monoclonal antibodies against MMP-2 suppressed ovulation and caused 
formation of luteinized, unruptured follicles (240). It was also shown that ovulation in rat 
perfused ovary could be inhibited when MMPs were blocked as late as 7 hours after LH 
surge (ovulation occurring at 9-12 hours aftei LH), but no significant inhibition occurred 
when the MMP inhibitor was added 9 hours after hCG (241). These data indicate that 
MMP-mediated collagenolysis is obligatory for ovulation in species like rat and sheep. 
Concomitant with the periovulatory increase in MMPs, LH/hCG stimulates an 
increase in mRNA expression and inhibitor activity for some of the TIMPs. TIMP-1 
mRNA expression increased after an LH stimulus in the mouse, rat, ewe, non-human 
primate, and human (234, 237, 242-247). Simultaneous increases in TIMPs and MMPs 
have been reported in numerous tissues and are believed to maintain proteolytic 
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homeostasis (222, 223, 248). The periovulatory increase in TIMPs may coordinate the 
actions of MMPs, limiting the location and extent of ECM remodeling to the follicle apex 
during the ovulatory process. It is also possible that increased TIMP expression and 
activity is necessary for ovulatory processes involving cellular proliferation, 
differentiation, or steroidogenesis (225). 
Additional information about the role of MMP/TIMP system in the reproductive 
tract was obtained from knockout and transgenic mice. These genetically modified 
animals did not show major alterations in the reproductive function. Deletion of MMP-9 
or TIMP-1 was not associated with an obvious reproductive phenotype in the initial 
description of these mice (249, 250), but subsequent analysis has revealed changes in the 
reproductive axis (251-254). In mice lacking MMP-9, the individual litters were smaller, 
and the percentage of infertile breeding pairs was increased (253). Similarly, TIMP-1-
null females achieved pregnancy at a lower rate than wild-type mice and had significantly 
fewer pups per litter (254). The confounding factor in understanding MMP action in 
ovarian and uterine physiology is that removal of one MMP or TIMP often results in 
compensation by other members of the MMP family. For example, deletion of MMP-7 
results in a 10-12-fold increase in MMP-3 and MMP-10 during uterine involution (255). 
Taken together, studies using genetic modification of the MMP system suggest that 
compensatory expression of MMP may prevent MMP-specific loss of fertility in 
experimental animal models. 
The regulation of the MMP system is extremely complex. Signals that regulate 
one MMP may differentially regulate other MMPs; signals that upregulate a certain MMP 
in one setting may have no effect or even an opposite effect depending on the absence or 
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presence of other signals or hormones. It is established that members of the MMP system 
that increase during the periovulatory period do so through cascade of events initiated by 
LH. The expression of mRNAs for MMP-1, MMP-9, and TIMP-1 increased in monkey 
granulosa cells in response to LH treatment in vitro similar to the effects of an ovulatory 
dose of gonadotropin in vivo (256). Blocking the endogenous surge of LH with Nembutal 
or phenobarbital inhibited the increase in MMP-13 mRNA as well as collagenase activity 
(198, 208, 225). Recent and current investigations have begun to examine signal cascade 
pathways mediated by LH, such as progesterone, PGs, and cytokines as well as their role 
in regulating the periovulatory increase in the MMP system. 
The pivotal role of progesterone in follicle rupture is supported by studies in 
which ovulation is compromised when progesterone synthesis is inhibited, progesterone 
action is blocked by treatment with the progesterone antagonist RU486, or progesterone 
receptors expression is lacking (199, 257-259). A role for progesterone in regulating the 
MMP system during the ovulatory process is apparent from reports that showed 
progesterone stimulated an increase in collagenase-like activity in ovine and hen 
follicular tissue; inhibition of progesterone synthesis or blocking progesterone action with 
RU486 decreased MMP activity in the rat and ewe (199, 260, 261). In the primate, 
treatment with the 3|3-hydrosteroid dehydrogenase inhibitor trilostane decreased the 
mRNA expression of MMP-1, MMP-9, MMP-7, TIMP-1, and TIMP-2 (237). 
Administration of exogenous progesterone to trilostane-treated macaques restored 
expression of MMP-1 and TIMP-1 to control levels. 
Additional potential LH-stimulated regulators of the MMPs and TIMPs are PGs. 
Inhibition of PG synthesis blocked the periovulatory increase in mRNA for MMP-1 and 
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MMP-13 as well as collagenase activity without affecting the gelatinases (234, 260, 262). 
In the ewe, inhibition of the preovulatory increase in PGs by administration of 
indomethacin suppressed the periovulatory rise in collagenase activity; this suppression 
of collagenolytic activity could be restored with exogenous PGE2 or PGF2a (260). For 
the TIMPs, blockage of PG production did not affect the mRNA expression patterns for 
TIMP-1, TIMP-2, and TIMP-3 in intact rat ovaries, nor did indomethacin administration 
affect production of MMP inhibitor activity in conditioned medium of rat granulosa cells 
(225, 263). Apparently, in rats, hCG regulation of TIMPs is PG independent. 
The above-described studies indicate that the MMP/TIMP system is indeed 
involved in proteolysis that occurs in periovulatory follicle and is regulated by the 
ovulatory gonadotropin surge. Gonadotropin acts either directly or via progesterone to 
increase MMP collagenolytic activity in the follicles. The role of PGs in the regulation of 
MMP/TIMP system is still unclear. 
2.4.3 Plasminofien activator/plasmin system 
The plasminogen activator/plasmin system is a multi-component system that 
contains not only proteolytic enzymes but also regulatory components including 
inhibitors, cofactors, cell surface receptors and binding proteins (Figure 7). The proteases 
of plasminogen activator system are characterized by their catalytic domain consisting of 
histidine, asparagine and serine residues (264). 
Two major types of plasminogen activators (PAs) have been identified in 
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Figure 7. Components of the plasminogen activator/plasmin 
system. PAI-1 = plasminogen activator inhibitor 1, PAI-2 = 
plasminogen activator inhibitor 2, tPA = tissue type 
plasminogen activator, uPA = urokinase type plasminogen 
activator, PN-1 = protease nexin 1. 
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activator (tPA). These two enzymes differ in their domain organization as well as the 
function of their non-catalytic regions (265). They are the products of distinct genes and 
are secreted as single-chain proteins. Whereas single-chain tPA is active, single-chain 
uPA is essentially inactive (pro-uPA) (266). Cleavage of pro-uPA by plasmin, kallikrein, 
Factor Xlla or cathepsin B yields the disulfide-linked double-chain active enzyme (267). 
The activation of the PA/plasmin system is initiated by the release of uPA or tPA from 
specific cells in response to signals (268). The two PAs have distinct targeting 
determinants in their non-catalytic regions: the "growth factor domain" of uPA directs the 
binding of the enzyme to a plasma membrane receptor (269, 270), whereas other 
structural domains on tPA (the "finger" region and the "kringles") allow its binding to 
fibrin and other components of ECM (271). The uPA receptor (uPAR) is present on the 
plasma membrane of monocytes, macrophages, fibroblasts, endothelial cells and 
keratinocytes (269, 270, 272). The uPAR binds both uPA and pro-uPA with similar 
efficacy. This receptor is comprised of at least one 55 kDa polypeptide chain, which is 
inserted in the plasma membrane through a glycerophospholipid anchor (273). Receptor 
bound uPA remains functionally active at the cell surface with a half-life of 4-5 hours 
(274). Studies have shown that receptor bound uPA can still be inhibited by PAI-1 or 
PAI-2 although with less efficacy, but it is protected from serum derived inhibitors like 
alpha 2-macroglobulin (274-276). Cell membrane-bound high-affinity receptors for tPA 
have not been identified. tPA binds to many proteins, and fibrin is by far the most 
efficient binding protein. In the presence of fibrin, tPA-catalyzed plasminogen activation 
occurs at least 100-fold more effectively than in its absence (277, 278). 
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Plasminogen is the preferred substrate for PAs. It is present in plasma and tissue 
extracellular fluids at a concentration of 1-2 uM (279). Plasminogen can associate with 
fibrin and other proteins via lysine-binding sites located in the kringles of its non-
catalytic portion (280). Plasminogen is a single-chain glycoprotein containing 790 amino 
acids with a molecular weight of approximately 92 kDa. Native plasminogen is referred 
to as Glu-plasminogen since it has a glutamic acid at its N-terminus. Glu-plasminogen is 
cleaved by plasmin at Lys76-Lys-77 to produce Lys-plasminogen (281). Both Glu- and 
Lys- plasminogen are activated to plasmin by a single PA-catalyzed cleavage at the 
Arg560-Val561 bond, which generates a double-chain protein held by two disulfide 
bonds. Plasmin catalysis the hydrolysis of Arg-x and Lys-x bonds in fibrin. In addition, 
several other proteins that comprise ECM can be easily degraded by plasmin, including 
gelatin, fibrinogen, type IV collagen, fibronectin, laminin, elastin, and proteoglycans 
(196, 282). 
The most important feature of this system is the amplification of the effect 
achieved by the reciprocal activation of pro-PAs and plasminogen on the cell surface. 
Both plasmin-catalyzed conversion of pro-PA to active PA and the subsequent active PA-
catalyzed conversion of plasminogen to plasmin are each accelerated (283). Due to the 
high concentration of plasminogen in plasma and body fluids, relatively low levels of PA 
production are effective enough to cause high levels of local plasmin production. At the 
same time, cell surface inhibition of PA activity can control the activation of PA/plasmin 
system in the microenvironment. 
Four arginine-specific serine-protease inhibitors (serpins) are of particular 
relevance to the PA/plasmin system (284): plasminogen activator inhibitor 1 (PAI-1), 
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plasminogen activator inhibitor 2 (PAI-2), protease nexin 1 (PN-1), and a2-antiplasmin. 
Serpins are so called suicide inhibitors that mimic the substrate and trap the enzyme in an 
inactive stable 1:1 complex (285). The inhibition involves reactive center cleavage and 
insertion of the reactive center loop into the inhibitor molecule, after which the covalently 
linked protease becomes translocated from one pole of the inhibitor to the opposite one 
(286, 287). The preferred target enzyme(s) of different serpins, as determined by the 
kinetic constants of complex formation, are different. 
PAI-1 is the major PAI in plasma. It has high affinity for tPA, both single-chain 
and double-chain, as well as for uPA. PAI-1 is a -54 kDa glycoprotein (288) that has two 
mRNAs (2.4 and 3.2 kb), which are thought to be different due to alternative 
polyadenylation sites. PAI-1 can exist in its native inhibitory form, in an inactive latent 
form, in complexes with proteases, and in a cleaved substrate form (289, 290). In 
addition, PAI-1 can form complexes with vitronectin while simultaneously retaining its 
activity (291, 292). PAI-1 forms complexes both with single-chain and double-chain-tPA 
and with double-chain uPA (288). However, PAI-1 has also been shown to form a 
reversible complex with single-chain uPA (293). Receptor bound active uPA is inhibited 
by PAI-1 and PAI-2, which leads to the inhibition of plasminogen activation (275, 294, 
295). 
Based on the amino acid and gene structure, PAI-2 belongs to the ovalbumin 
subgroup of the serpin superfamily (296, 297). Its gene is transcribed to a 2.0 kb mRNA 
(296). PAI-2 protein exists in two forms: a nonglycosylated intracellular form and a 
glycosylated secreted extracellular form (298). PAI-2 inhibits uPA rapidly but inhibits 
tPA very slowly (284). 
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PN-1 inhibits uPA, plasmin, and thrombin; its reactivity towards thrombin (but 
not towards the other two enzymes) is dramatically enhanced in the presence of heparin 
(299). PN-1 is mainly produced by fibroblasts, and after secretion it can either stay 
associated with the cell surface or is released from the cell. Two forms of PN-I cDNA 
(designated a and P) have been identified (300). These differ only by the insertion of 
three nucleotides into the coding sequence which is achieved by utilization of an 
alternative splice acceptor site in the PN-1 gene. Both forms have been expressed in 
mammalian cells and inhibit both thrombin and uPA. The dual role of PN-I as an 
inhibitor of fibrin deposition and removal suggests that it may be designed to blunt the 
effect of multiple enzymatic pathways (301). 
The serpin inhibitor a2-antiplasmin is the primary inhibitor of plasmin (302). It 
forms a complex with plasmin by occupying the plasmin kringle domains, i.e. the lysine 
binding sites. It is a fast inhibitor of free plasmin both in circulation and solution. When 
plasmin/plasminogen is bound to the cell surface, its lysine binding sites are occupied, 
therefore a2-antiplasmin acts more slowly (303). 
Another inhibitor of PA/plasmin system is a2-macroglobulin, which is found in 
circulation in vast quantities (281, 304). This large glycoprotein can trap proteases and 
their inhibitor complexes. a2-Macroglobulin complexes are internalized by means of 
low-density lipoprotein-related receptor LRP (305). a2-Macroglobulin binds 
plasminogen activators and their inhibitor complexes as well as plasmin. Cell-bound 
plasmin is protected from a2-macroglobulin (295). 
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2.4.4 PA/plasmin system in ovulation 
PAs may play a role in ovulation (306, 307). Plasminogen is present in the 
follicular fluid, and plasmin can weaken the follicular wall in vitro. Intra-ovarian 
administration of PA/plasmin inhibitors or antisera suppresses ovulation in the rat and 
ewe (147, 204, 308). Gonadotropin releasing hormone (GnRH) induced plasmin 
generation within the apex of ovine pre-ovulatory follicles and the secretion of PA by the 
ovarian surface (308). Furthermore, surgical abrasion of ovarian surface epithelium 
abolished the production of PA within the follicles and prevented rupture of follicular 
wall. 
The hypothesis that PAs are responsible for follicle rupture during ovulation was 
reinforced by studies showing that tPA and uPA are present in the rat ovary, and PA 
expression and activity were regulated by gonadotropins in a cell-specific and time 
coordinated manner (208, 309-314). tPA expression was induced by gonadotropins, with 
a distinct pattern of expression in different ovarian compartments. tPA was expressed in 
both granulosa and theca interstitial cells in periovulatory follicle (314), and maximum 
tPA mRNA levels were measured in granulosa cells just prior to ovulation (312). hCG 
injection increased tPA activity in a time-dependent manner as measured by fibrin 
overlay, reaching a maximum immediately prior to ovulation and declining thereafter 
(315). In contrast, mouse periovulatory granulosa cells produced only uPA, while tPA 
mRNA was found in mouse theca interstitial cells (316, 317). Both uPA in granulosa 
cells and tPA in theca interstitial cells were dramatically upregulated before ovulation, 
providing redundant mechanisms for plasmin formation during ovulation. tPA mRNA 
expression in granulosa cells and uPA mRNA expression in both granulosa and theca 
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cells increased 12 hours after GnRH injection in bovine follicles (318). In the rhesus 
monkey, granulosa cell-derived tPA mRNA was substantially elevated in response to 
hCG administration (319). tPA expression and activity reached maximum levels just 
before ovulation, indicating that tPA may be important for ovulation to occur in non-
human primates. 
Similar to other proteolytic systems, PAs and their inhibitors are regulated by the 
same stimuli. In a recent study, hCG administration increased tPA, uPA, PAI-1 and PN-I 
mRNA expression in bovine follicle wall homogenates (320). PN-1, PAI-1 and tPA 
mRNA expression decreased near the expected time of ovulation, whereas uPA mRNA 
levels remained high. PN-1 concentration in follicular fluid decreased and reached the 
lowest level at the time of ovulation, whereas plasmin activity in follicular fluid increased 
significantly after hCG. In rats, PAI-1 was secreted in a highly regulated manner, mainly 
by theca interstitial cells (315). The highest levels of PAI-1 in the rat ovary were found 
about 6 hours before ovulation and mainly in the theca interstitial cells and ovarian 
stroma, which encapsulate the follicle (314). In mice, the expression of PAI-1 and PAI-2 
was found to be low during the periovulatory period, but expression of PN-I by granulosa 
cell was high during the entire periovulatory period (317). In bovine granulosa and theca 
cells, PAI-1 mRNA expression increased 12 hours after GnRH administration, whereas 
PAI-2 in granulosa cells increased only 24 hours after GnRH injection (318). In rhesus 
monkey follicular fluid, PAI-1 protein measured by Western blot analysis and PAI-1 
activity measured by reverse fibrin overlay reached maximum levels 24 hours after hCG 
administration (319). It is probable that PA inhibitors act in a manner similar to that of 
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TIMPs to coordinate the actions of PAs to achieve maximum proteolytic activity limited 
to the follicular apex. 
The above-described studies suggest that the expression and function of PAs and 
their inhibitors are regulated by the ovulatory gonadotropin surge. However, it remains 
unclear whether in periovulatory follicle gonadotropin acts directly to regulate proteolysis 
or via mediators. There is conflicting data about the involvement of PGs in regulation of 
PA/plasmin system and plasminogen dependent proteolysis in periovulatory follicles. The 
dose of indomethacin that completely blocked ovulation in rats had no effect on either the 
magnitude or the time-course of PA activity after intra-peritoneal co-administration with 
hCG (321). In cultured rat granulosa cells, PGE2 induced and indomethacin inhibited LH 
stimulated production of tPA (322). Moreover, after 24 hours of treatment, PGE2 alone 
stimulated PA activity in mural and cumulus granulosa cells in vitro. When administered 
before or 3.5 hours after LH administration, the progesterone receptor selective 
antagonist Org 31710 significantly suppressed ovulation in perfused rat ovary (323). Org 
31710 treatment also decreased the levels of PGE2, PGF2a, and PA activity. 
Intrafollicular administration of indomethacin significantly decreased tPA, PAI-1 and 
PAI-2 mRNA abundance in bovine periovulatory granulosa cells as well as uPA and 
PAI-1 mRNA abundance in theca cells (318). In the same study, tPA activity in the 
follicle apex was significantly decreased in response to indomethacin treatment. In 
conclusion, while the involvement of PGs in regulation of PAs and their inhibitors in rat 
periovulatory follicle is still unclear, there is no data about the role of PGs in 
gonadotropin induced plasmin dependent proteolysis in primates. 
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The physiological role of tPA, uPA, PAI-1 and plasmin in ovulation were further 
assessed by extensive studies on protease deficient mice (324-326). Ovulation efficiency 
(mean number of ova per mouse) was determined during gonadotropin-induced ovulation 
in young immature mice as well as in adult cycling mice during estrous cycle (325). 
Plasminogen deficient mice had decreased ovulation rates. Ovulation efficiency was 
normal in mice lacking expression of either tPA, uPA, or PAI-1. However, in tPA/uPA 
double knockout mice there was 25% reduction in ovulation efficiency. PN-1 deficient 
mice showed decreased male fertility but there were no changes in female reproductive 
function (327). As mentioned above, the long-term inactivation of a single protease gene 
from the blastocyst stage may induce compensatory mechanisms within the protease 
family. 
Taken together, these studies suggest that controlled and directed proteolytic 
activity generated by PAs and modulated by their inhibitors is involved in the 
mechanisms which lead to rupture of selected follicles during ovulation. However, there 
are significant interspecies differences regarding the type of PAs and their inhibitors 
which are involved in ovulation. Although the ovulatory gonadotropin surge appears to 
regulate proteolytic activity in the periovulatory follicle, it is not clear whether the 
temporal and spatial restriction of proteolysis is achieved by engaging mediators like PGs 
and progesterone. Extremely little is known about PA/plasmin system expression and 
regulation in human periovulatory follicle, which makes very relevant the data obtained 
from non-human primates. 
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2.4.5 ADAMTSs family of metalloproteases and cathepsin L in ovulation 
The ADAMTSs are a recently discovered gene family of secreted-type proteases 
(328-330). Currently, the ADAMTS family consists of 19 members revealed from the 
complete sequence of the human genome (331). 
ADAMTSs exert proteolytic activity and biological functions in different tissues 
such as skin and cartilage (332-334). ADAMTS-1 has been shown to have antiangiogenic 
activity (335). ADAMTS-1-/- mice have considerably reduced size and weight (about 
70% of the wild-type or heterozygos animals), obstructive fibrosis in the kidneys, 
disrupted capillary network in adrenals and impaired female fertility (336). It is believed 
that ADAMTSs may be instrumental for expansion of cumulus-oocyte complex (COC). 
COC expansion is a complex process that requires cumulus mucification as well as 
extensive reorganization of ECM, with both formation and degradation of its components 
(337). 
ADAMTS-1, along with ADAMTS-4, -5, -8, and -14, comprises a functional 
group of proteases with activities against chondroitin sulfate proteoglycans including 
aggrecan, versican, and brevican (334, 338, 339). Versican, one of the preferred 
substrates of ADAMTS' activity, is highly inducible by LH in periovulatory follicles 
(340). In mice, COCs collected from oviducts contained cleavage product of versican 
(341). These data indicate that versican degradation possibly by ADAMTS may be one of 
the events that promotes detachment of COCs. In the ovary, ADAMTS-1 was selectively 
induced by an ovulatory dose of LH or hCG (220, 235). This induction was clearly 
progesterone and progesterone receptor dependent (219, 220). These studies suggested 
that ADAMTS-1 has a critical downstream role in mediating the progesterone receptor-
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regulated ovarian activity that culminates in the rupture of follicles. Subfertility in 
ADAMTS-1 null female mice due to the impaired ability to ovulate further supports a 
key role for ADAMTS-1 in ovulation (336, 342). 
Cathepsin L is another LH and progesterone receptor-regulated gene in the ovary 
that was identified by cDNA array technology (219). Cathepsin L is a member of the 
papain family of enzymes. It is commonly a lysosomal protease, but it is also secreted 
from certain endocrine cells, such as Sertoli cells of the testis and placental trophoblasts 
and from certain tumors (343). The function of cathepsin L in the ovary appears to be 
complex. This enzyme is expressed in granulosa cells of follicles at several different 
stages of development in response to both FSH and LH (219). In addition, its expression 
in ovulatory follicles is impaired in progesterone receptor null mice. It is possible that 
cathepsin L may be a mediator of insulin-like growth factor binding protein's (IGFBP) 
clearance in the ovarian follicles, or like cathepsin G, it may activate protease-activated 
G-protein coupled receptors on granulosa cells (344, 345). The role of cathepsin L in 
ovulation is yet unclear. 
The purpose of the study presented in this dissertation is to elucidate the 
mechanisms by which ovulatory gonadotropin surge regulates the proteolytic 
activity in periovulatory follicles. ECM degradation initiated by proteolytic enzymes 
is a vital part of successful ovulation. Although there is ample data to indicate a role 
for the PA/plasmin proteolytic system in ovulation, very little is known about the 
expression and regulation of these proteolytic enzymes and their inhibitors in the 
primate ovary. The importance of PGs in follicle rupture is largely accepted, but 
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there is no conclusive evidence linking PGs to proteolysis in ovulation. This study 
addresses the role of PGE2 in the regulation of the PA/plasmin system in the 
primate periovulatory follicle in vivo and in vitro. In addition, one goal of the 
present investigation is to identify specific EP receptors through which PGE2 acts to 
mediate gonadotropin-induced proteolysis. These data will provide information that 
can be used both to induce and prevent ovulation as needed. The results will support 
further studies of receptor-selective agonists and antagonists for the treatment of 




Specific Aim #1 
There are 4 known PGE2 receptors: EP1, EP2, EP3 and EP4. All 4 are G-protein 
coupled receptors. Different tissues express different subsets of EP receptors. 
Regulation of these receptors is tissue specific. 
Aims: Determine 1) which EP receptors are expressed in peri ovulatory granulosa cells 
and 2) if EP receptor expression in the ovulatory follicle is gonadotropin regulated. 
Hypothesis: One or more EP receptors are expressed in periovulatory granulosa cells. 
The ovulatory gonadotropin surge increases EP receptor expression to peak towards the 
end of periovulatory period when PGE2 levels are elevated. 
Experiments: In Experiment #1, the expression of all 4 EP receptor mRNAs was 
measured by real-time RT PCR in granulosa cells collected before (0 hour) and 12, 24, 
and 36 hours after administration of an ovulatory dose of hCG. The changes in mRNA 
levels of EP receptors showed whether the ovulatory gonadotropin regulates EP receptor 
expression on the level of gene transcription. 
Experiment #2 examined the protein expression of EP receptor proteins by 
immunofluorescence on the frozen tissue sections of ovaries obtained 0, 12, 24, and 36 
hours after hCG administration and on paraffin sections of the ovaries obtained on days 
0, 1, and 2 after LH surge of the natural cycle. The experiment showed the expression of 
EP receptor proteins during the periovulatory period in different compartments of the 
ovarian wall (mural granulosa cells and ovarian stroma). 
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Experiment #3 examined EP receptor protein expression in granulosa cells by Western 
blot analysis in order to quantify the changes in EP receptor protein levels during the 
periovulatory period. These experiments determined whether EP receptor protein 
increased after gonadotropin administration to reach peak levels towards the end of the 
periovulatory period. 
Specific Aim #2 
EP receptors are coupled with different G proteins and activate different second 
messengers. Activation of functional EP1 receptors results in an increased [Ca2+]i. 
EP2 and EP4 are coupled to Gas to activate adenylyl cyclase and increase cAMP. 
EP3 receptor activation can either increase or decrease cAMP levels or increase 
[Ca2+]i, depending on the specific G protein (Gas, Gai, or Gaq respectively) 
coupled to the intracellular portion of this receptor. 
Aims: Determine 1) which EP receptors are functional and 2) if EP receptor function 
changes during the periovulatory period. 
Hypothesis: One or more EP receptors are functional and can activate second messengers 
in response to PGE2 or receptor selective agonists. The responsiveness of functional EP 
receptors is modulated by an ovulatory dose of gonadotropin. 
Experiments: In Experiment #1, cAMP levels were measured in granulosa cells obtained 
24 and 36 hours after hCG administration. The choice of two time points (24 and 36 
hours after hCG) was based on the observation that in the non-human primate, PGE2 
levels measured in follicular fluid start to increase 24 hours after hCG administration and 
reach the maximum level 36 hours after hCG (79, 99). Granulosa cells were cultured for 
16 hours with PGE2 or EP receptor selective agonists or antagonists. The levels of cAMP 
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were measured in harvested media by ELISA. The increase of cAMP in response to 
PGE2 confirmed the functionality of EP receptors that are linked to adenylyl cyclase. The 
EP selective agonists and antagonists identified the specific EP receptors that modulate 
cAMP levels. The change between 24 and 36 hours after hCG in the ability of EP 
receptor agonists to stimulate cAMP production confirmed that the function of these 
receptors is regulated by hCG. 
Experiment #2 tested the function of EP1 by measuring [Ca2+]i in granulosa cells 
obtained 24 and 36 hours after hCG administration. The cells loaded with a dye that 
fluoresces when bound to Ca2+ were treated with PGE2 or PGE2+EP1 receptor 
antagonist. PGE2 was used as an EP1 ligand, and an antagonist which blocks PGE2 
activity at EP1 receptors was used to differentiate between EP1 or EP3 induced 
responses. Confocal images were taken before and after treatments, and these images 
were analyzed using Metamorph software to quantify [Ca2+]i. Increased [Ca2+]i after 
PGE2 treatment that can be attenuated or abolished by the EP1 receptor antagonist 
indicated EP1 receptor activation of the signaling pathway. 
Specific Aim #3 
In different species, the members of PA/plasmin system (tPA, uPA, and their 
inhibitor PAI-1) are involved in proteolytic degradation of the ovarian ECM. The 
activity of PA system was shown to increase just before expected time of ovulation, 
when the highest levels of PGE2 were measured in follicular fluid. 
Aims; Determine 1) which members of PA/plasmin system are expressed in 
periovulatory granulosa cells and 2) whether the expression of the enzymes and the 
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proteolytic activity of PA system components are regulated by the ovulatory 
gonadotropin surge and PGs. 
Hypothesis: tPA, uPA, and PAI-1 are expressed in peri ovulatory granulosa cells. Their 
expression and proteolytic activity are regulated by gonadotropin. In the late 
periovulatory period, gonadotropin regulation of PA system is mediated via PGs. 
Experiments: In Experiment #1, mRNA levels of tPA, uPA, and PAI-1 were measured by 
real time RT-PCR in granulosa cells obtained 0, 12, 24, and 36 hours after hCG 
administration. The changes in mRNA levels during the periovulatory period determined 
whether ovulatory gonadotropin regulates the expression of PAs and their inhibitor. To 
determine if PGs regulate components of the PA system, mRNA levels of tPA, uPA, and 
PAI-1 were measured in granulosa cells that were obtained 36 hours after hCG 
administration from the animals treated with the PG synthesis inhibitor celecoxib. 
In Experiment #2, tPA, uPA, and PAI-1 proteins were detected by immunofluorescence 
on frozen sections from the ovaries that were obtained 0, 12, 24, and 36 hours after hCG 
administration. In addition, the expression of these proteins was studied in the ovaries of 
animals that received PG synthesis inhibitor treatment during the periovulatory period. 
Experiment #3 quantified tPA and PAI-1 in monkey follicular fluid. ELISA kits were 
used to measure PAs and their inhibitor in follicular fluids obtained 0, 12, 24, and 36 
hours after hCG administration. The changes in secreted protein levels confirmed that 
ovulatory gonadotropin regulates protein levels of tPA and its inhibitor PAI-1. 
Experiment #4 detected plasminogen-dependent proteolysis on the frozen ovarian 
sections by in situ zymography. Proteolytic activity of the PA system was studied in 
ovaries obtained 0, 12, 24, and 36 hours after hCG administration. Additional ovaries 
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were obtained 36 hours after hCG administration from the animals that received the PG 
synthesis inhibitor celecoxib treatment during the periovulatory period. The results of the 
experiment elucidated whether PA activity is gonadotropin and PG regulated. 
Specific Aim #4 
PGE2 is the bioactive PG known to be important for follicle rupture during 
ovulation. IntrafoIIicular PGE2 levels as well as the expression and function of 
multiple EP receptors increase in the late periovulatory period when proteolytic 
enzymes like PAs cause the degradation of follicle wall. 
Aims: Determine whether PGE2 is the PG that regulates the components of the PA 
system. If PGE2 is involved in the regulation of PA system, then determine which EP 
receptors transduce PGE2 effects. 
Hypothesis: The induction of PA proteolytic activity by the ovulatory gonadotropin surge 
is mediated by PGE2 in the late periovulatory period. The expression of tPA and PAI-1 is 
differentially regulated by PGE2 acting through specific EP receptors. 
Experiments: This experiment detected tPA and PAI-1 proteins in cultured granulosa 
cells. Cells were collected before hCG administration and cultured with an ovulatory 
dose of hCG and a PG synthesis inhibitor to inhibit endogenous PGE2 synthesis. After 24 
hours in vitro, the cells received PGE2 treatment. Increased protein expression with 
PGE2 treatment confirmed that hCG regulation of tPA and PAI-1 was mediated by 
PGE2. To identify EP receptors through which PGE2 acts to regulate tPA and PAI-1, 
additional granulosa cells received treatment with EP receptor selective agonists. 
Changes in the expression of tPA and PAI-1 proteins in EP receptor selective agonist 
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STUDIES FOR SPECIFIC AIMS #1 AND #2 
4.1 Materials and Methods for Specific Aims #1 and #2 
Animals 
Granulosa cells and whole ovaries were obtained from adult female cynomolgus 
macaques at Eastern Virginia Medical School (Norfolk, VA). All animal protocols and 
experiments were approved by the Eastern Virginia Medical School Animal Care and 
Use Committee and were conducted in accordance with the National Institutes of Health 
Guide for the Care and Use of Laboratory Animals. Monkeys were maintained in 
temperature-controlled rooms on a 12-hour light, 12-hour dark cycle. Animals were fed 
commercial monkey chow and had water available at all times. Adult females with 
regular menstrual cycles were checked daily for menstruation; the first day of 
menstruation was designated day 1 of menstrual cycle. Blood samples were obtained 
under ketamine chemical restraint (5-10 mg/kg body weight) by femoral venipuncture, 
and serum was stored at -20°C. Aseptic surgeries were performed in a dedicated surgical 
suite under isofluorane anesthesia and involved midline laparotomy or laparoscopy. 
A controlled ovarian stimulation model developed for the collection of multiple oocytes 
for in vitro fertilization was used to obtain monkey granulosa cells (257, 346). Beginning 
within 3 days of initiation of menstruation, recombinant human FSH (90 IU daily, Serono 
Reproductive Biology Institute, Rockland, MA and Organon, Inc, a part of Schering 
Plough, Inc., Roseland, NJ) was administered for 6-8 days, followed by daily 
administration of 90 IU of recombinant human FSH plus 60 IU r-hLH (Serono) for 2 
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days to stimulate the growth of multiple follicles. The GnRH antagonist Antide (0.5 
mg/kg body weight; Serono) was also administered daily to prevent an endogenous 
ovulatory LH surge. Adequate follicular development was monitored by serum estradiol 
levels and ultrasonography (347, 348). Follicular aspiration was performed by 
laparotomy and laparoscopy before (0 h) or 12, 24, and 36 hours after administration of 
] 000 IU r-hCG (Serono). In spontaneous menstrual cycles, follicle rupture in monkeys 
occurs approximately 40 hours after the ovulatory gonadotropin surge (349), so these 
times span the periovulatory interval. To obtain granulosa cells, each follicle was pierced 
with a 22-gauge needle, and the aspirated contents of all follicles larger than 4 mm in 
diameter were pooled. Whole ovaries were also obtained from monkeys undergoing 
ovarian stimulation. Additional whole ovaries were collected from monkeys experiencing 
spontaneous menstrual cycles around the expected time of the endogenous LH surge 
(349). These ovaries were obtained before, during, 1 day after, and 2 days after the LH 
surge (n = 2-3/day) as defined by serum estradiol, LH and progesterone concentrations 
before and at the time of organ removal (350). Monkey kidney tissue was obtained at 
necropsy. 
Tissue preparation 
Monkey granulosa cells and oocytes were pelleted from follicular aspirates by 
centrifugation. Oocytes were mechanically removed, and a granulosa cell-enriched 
population of the remaining cells was obtained by Percoll gradient centrifugation (350). 
Viability of granulosa cell-enriched preparations averaged 76.2% as assessed by trypan 
blue exclusion. Cells were either used immediately for cell culture or were frozen in 
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liquid nitrogen and stored at -80°C for preparation of total RNA or cell lysates. Whole 
stimulated ovaries were bisected, maintaining at least two periovulatory follicles greater 
than 4 mm in diameter on each piece. The pieces were covered with O.C.T. Compound 
(Sakura, Tokyo, Japan), frozen in liquid propane and stored at -80°C. Natural cycle 
ovaries were fixed in 4% paraformaldehyde and embedded in paraffin. Monkey kidney 
tissue was either frozen in liquid propane and stored at -80°C or was fixed in 4% 
paraformaldehyde and embedded in paraffin. 
Real-Time RT-PCR 
EP receptor mRNA levels were analyzed by real-time RT-PCR using a Roche 
LightCycler (Roche Diagnostics, Indianapolis, IN). Total RNA was obtained from 
granulosa cells using Trizol reagent (Invitrogen, Rockville, MD), treated with DNase, 
and reverse transcribed as previously described (51). PCR was performed using the 
FastStart DNA Master SYBR Green I kit (Roche) following manufacturer's instructions 
and using 0.5 uM primers and 4 mM MgC^. Primers were designed using LightCycler 
Probe Design software (Roche) based on the human or monkey sequences (Table 1) and 
span an intron whenever possible to prevent undetected amplification of genomic DNA. 
PCR products were sequenced (Microchemical Core Facility, San Diego State University, 
CA) to confirm amplicon identity. At least 5 log dilutions of the sequenced PCR product 
were included in each assay and used to generate a standard curve. When amplification 
was not detected in two EP1 samples, the lower limit of detection of the assay (15 
copies/40 ng of cDNA) was applied for statistical analysis. For each sample, the content 
of each EP receptor and p-actin mRNA was determined in independent assays. No 
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amplification was observed when monkey cDNA was omitted. All data were expressed 
as the ratio of EP mRNA to P-actin mRNA for each sample. Intra- and inter-assay 
coefficients of variation were less than 10%. 
Immunofluorescent detection of EP receptors 
Frozen ovarian and kidney tissues were sectioned at 10 um and fixed with 
buffered 10% formalin. After antigen retrieval using Antigen Retrieval Citra treatment 
(BioGenex Labs, San Ramon, CA), the sections were blocked with 5% non-immune goat 
serum (Vector Laboratories, Burlingame, CA) in phosphate-buffered saline containing 
0.1% Triton (PBS-Triton). Sections were then incubated overnight with either primary 
antibody generated against one of the EP receptors [EP1 (1 ng/ml). EP2 (5 u.g/ml), EP3 
(2 p.g/ml), EP4 (3 u,g/ml)] or primary antibody+blocking peptide (Cayman Chemicals, 
Ann Arbor, MI), followed by incubation with a Alexa Fluor 488 conjugated anti-rabbit 
secondary antibody (1:500; Molecular Probes, Eugene, OR). After incubation with 1% 
Sudan Black in 70% methanol, the slides were coverslipped using Vectashield medium 
(Vector Labs). All images were obtained using an Olympus BX41 fluorescent 
microscope fitted with a DP70 digital camera and associated software (Melville, NY). 
Paraffin embedded ovarian and kidney tissue sections (5 um) were deparaffinized, 
exposed to antigen retrieval as described above, and incubated with Image-iT signal 
enhancer (Molecular Probes). After exposure to 5 % non-immune serum block in PBS-
Triton, sections were incubated with streptavidin and biotin (Vector Labs). After the 
overnight incubation with either primary antibodies against each EP receptor [EP1 (3 
p,g/ml), EP2 (1 ug/ml), EP3 (3 p-g/ml), EP4 (3 |J.g/ml)] or with primary 
74 
antibody+blocking peptide followed by biotinylated anti-rabbit secondary antibodies 
(1:200, Vector Labs), the sections were treated with Streptavidin-Alexa Fluor 488 
(Molecular Probes), then with 1% Sudan Black, coverslipped and photographed as 
described above. 
Western blotting 
Western blotting was performed on enriched granulosa cell populations obtained 
from monkey and human follicular aspirates. Human luteinizing granulosa cells were 
obtained after oocyte removal from follicular aspirates from patients experiencing 
ovarian stimulation at The Jones Institute for Reproductive Medicine, EVMS. This use 
of discarded human granulosa cells does not constitute human subjects research as 
determined by the EVMS Institutional Review Board. No information is obtained 
regarding an individual patient's diagnosis or treatment protocol. However, most patients 
receive hCG 34-36 hours prior to follicle aspiration, so these human cells are very similar 
to monkey granulosa cells obtained 36 hours after hCG administration. Human granulosa 
cells were enriched by Percoll gradient centrifugation as described above for monkey 
granulosa cells. Denatured granulosa cell lysates were loaded onto 4-20% gradient 
polyacrylamide Tris-HCl gels (Bio-Rad, Hercules, CA). Four dilutions of granulosa cell 
lysates were loaded onto the gel to show that the samples were in the linear range of 
detection. Proteins were transferred to polyvinylidene fluoride membranes (Imobilon, 
Millipore, Billerica, MA), and western blotting was carried out with rabbit polyclonal 
primary antibodies against EP1 (6 i^g/ml), EP2 (5 jig/ml), and EP3 (4 pg/ml) and an anti-
rabbit immunoglobulin G (IgG)-horseradish peroxidase conjugated secondary antibody 
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(1:10,000; Amersham, Piscataway, NJ, USA). Bands were detected by enhanced 
chemiluminescence (ECL; Amersham). Blots were then stripped of primary and 
secondary antibodies following instructions provided by the membrane manufacturer, and 
western blotting was performed on the stripped membranes using a mouse anti-tubulin 
primary antibody (1:1000; Sigma) and anti-mouse IgG-horseradish peroxidase conjugate 
secondary antibody (1:20,000; Amersham). The molecular size of bands representing 
each EP receptor and tubulin were determined by comparison to prestained standards 
(Bio-Rad). Films were scanned and analyzed densitometrically using SigmaGel software 
(Jandel Scientific, San Rafael, CA). EP content of each granulosa cell sample is 
expressed as EP protein/tubulin ratio. 
Granulosa cell culture 
Monkey granulosa cells were plated on 48 well or 96 well tissue culture plates or 
Lab-Tek chamber slides (Nalge Nunc International, Rochester, NY) coated with 
fibronectin (Sigma, St. Louis, MO, USA) at a concentration of 10,000 cells/100 ul 
medium. The cells were cultured in serum free DMEM-Ham's F12 medium containing 
insulin (2 jag/ml), transferrin (5 ug/ml), selenium (0.25 nM), aprotinin (10 (ag/ml), and 
human low-density lipoprotein (25 |J.g/ml) (351). 
cAMP measurements 
Cells were cultured with PGE2 (luM), PGE2+the EP1/EP2 antagonist AH6809 
(10 uM), the EP2 agonist butaprost (10 uM), the EP3 agonist sulprostone (luM) 
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(Cayman), or no treatment (control). Media were stored at -20°C until acetylated prior to 
assay for cAMP by enzyme immunoassay (Cayman), which was performed and analyzed 
following kit instructions. The lower limit of detection for the assay was used for 
statistical analysis when the calculated cAMP concentration of one control sample was 
below the level of detection. All cAMP levels were normalized to the protein content of 
cultured cells as determined by the bicinchoninic acid method (Sigma). Preliminary 
studies showed a dose dependent increase in cAMP production in response to PGE2 
(Appendix 1), and a linear increase in cAMP levels measured between 4-24 hours in the 
media of cultured granulosa cells treated with PGE2 (1 uM, Appendix 2). For studies 
presented here, media for cAMP assay was collected 16 hours after agonist/antagonist 
addition. For each animal, data are presented as a ratio of the EP agonist-stimulated 
cAMP level to the cAMP level in the untreated (control) cultures. 
TCa2+li measurements 
For [Ca2+]i (intracellular Ca2+ concentration) measurements, granulosa cells 
were incubated for 30 minutes in Hanks' balanced salt solution containing 1.8 mM CaCb 
and the fluorescent dye Fluo 3AM (Molecular Probes) at 1:1000 dilution. The basal 
fluorescent emission of cells was determined before treatment (0 seconds (sec)). 
Granulosa cells were then stimulated with PGE2 (1 uM) and imaged every 20 seconds for 
2 minutes. Finally, cells were exposed to the calcium ionophore calcimycin (10 uM, 
Calbiochem, San Diego, CA); only cells with increased fluorescence after calcimycin 
treatment were included in quantitative analyses. A second culture of cells received 60 
second pretreatment with AH6809 (10 uM), after which PGE2 was added, and the cells 
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were imaged as described above. Images of cells were obtained using a confocal 
microscope (Zeiss LSM - 510, Carl Zeiss Inc, Thornwood, NY) at absorption and 
emission wavelengths of 506 nm and 526 nm, respectively. For each treatment, ten 
calcimycin-responsive cells were analyzed for fluorescence using MetaMorph software 
(Molecular Devices, Sunnyvale, CA), and [Ca2+]i was calculated using the following 
formula: [Ca2+]i=Kd (Ca2+) X (F-Fmin)/Fmax-F, where Kd (Ca2+) = 325 nM, Fmin is 
the fluorescence measured in the absence of Fluo 3AM in the medium, F is the 
fluorescence of the cells in the medium containing Fluo 3 AM, and Fmax is the 
fluorescence after addition of calcimycin (352, 353). For each animal, [Ca2+]i of cells 
before treatment was set equal to 1.0, and [Ca2+]i in the same cells after treatment was 
expressed relative to pretreatment levels. 
Data analysis 
All data were assessed for heterogeneity of variance and log transformed when 
Bartlett's test yielded a significance of <0.05. Data presented in Fig. 7 (Panels C and D), 
Fig. 10 and Fig. 11 were log transformed before further analysis. In all figures, 
untransformed data are presented. PCR and Western blot data were assessed by ANOVA. 
cAMP and [Ca2+]i data were assessed by ANOVA with 1 repeated measure. In all cases, 
post hoc analysis was performed using Duncan's Multiple-Range test. In addition, EP2 
protein levels at 0 hour and 36 hours were compared by 2-tail t-test. Statistical analyses 
were performed using StatPak v4.12 software (Northwest Analytical, Portland, OR). Data 
are presented as mean+standard error of the mean (SEM), and significance was assumed 
atp value<0.05. 
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4.2 Results for Specific Aims #1 and #2 
EP mRNA expression by monkey granulosa cells 
Monkey granulosa cell expression of EP receptor mRNA was examined before 
and after administration of an ovulatory dose of hCG at times which span the 40-hour 
long periovulatory interval in primates. EP1, EP2, EP3, and EP4 mRNA was detected in 
granulosa cells before (0 hour) hCG administration (Figure 8). Levels of EP1, EP2, and 
EP4 mRNA did not change in response to hCG exposure. In contrast, EP3 mRNA levels 
were low before (0 hour), elevated at 12 hours, and remained elevated 24-36 hours after 
hCG administration. 
EP receptor proteins in monkey granulosa cells 
EP1 receptors were not detected in granulosa cells of monkey periovulatory 
follicles by immunofluorescence at 0 and 12 after hCG (Figure 9A and data not shown). 
There was sporadic EP1 fluorescence in granulosa cells of ovaries obtained 24 hours after 
hCG, but the intensity of fluorescence for EP1 increased notably in granulosa cells of 
ovaries obtained 36 hours after hCG (Figure 9B, C). EP1 immunofluorescence was also 
present in the monkey kidney (Figure 9D), confirming previous reports (124, 155) and 
serving as a positive control. EP1 was not detected when the primary antibody was 
omitted (data not shown) or preincubated with the blocking peptide (Figure 9C, D insets). 
The EP2 protein was detectable by immunofluorescence in granulosa cells of 
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Figure 8. EP receptor mRNA expression in monkey granulosa 
cells. Granulosa cells were obtained from monkeys 
experiencing controlled ovarian stimulation before (0 hour) and 
12, 24, and 36 hours after hCG administration. mRNA were 
determined by real time RT-PCR; all mRNA levels are 
expressed relative to P-actin. Data are presented as mean±SEM 
(n=4-5 animals/time point). In panel C, groups with different 
letters are different by ANOVA and Duncan's Multiple-Range 
test, p value<0.05. Modified from Markosyan et al. (376). 
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0 hour 24 hour 36 hour Kidney 
Figure 9. Immunofluorescent detection of EP receptors in monkey granulosa 
cells. Ovaries were obtained from monkeys experiencing controlled ovarian 
stimulation at 0 h (A, E, I, M), 24 h (B, F, J, N), and 36 h (C, G, K, O) after 
hCG administration. In each periovulatory follicle shown, the antrum (a) is in 
the upper right, granulosa cells (gc) are central, and the ovarian stroma (s) is 
in the lower left portion of the image. Immunodetection (bright green) of 
EP1 (A, B, C), EP2 (E, F, G), EP3 (I, J, K), and EP4 (M, N, O) in 
periovulatory follicles is shown. Immunodetection of EP1 (D), EP2 (H), EP3 
(L), and EP4 (P) in monkey kidney served as a positive control. No 
fluorescence was observed when the primary antibodies were preabsorbed 
with the blocking peptide (C, D, G, H, K, L, O, P insets) or when the primary 
antibody was omitted (not shown). Ovarian images shown are representative 
of 3-4 animals/time point. For all panels, bar = 50 um. Modified from 
Markosyan et al. (376). 
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data not shown). EP2 immunofluorescence was not observed in the ovarian stroma. 
Monkey kidney tissue exhibited low levels of EP2 protein detection (Figure 9H) as 
reported by others (140, 155). As with EP1, EP2 immunofluorescence was absent when 
the primary antibody was omitted or preincubated with the blocking peptide (Figure 9G, 
H insets and not shown). Western blotting using this EP2 antibody detected a single 52 
kDa band in lysates of granulosa cells obtained 0, 24, and 36 hours after hCG (Figure 
10A), which was eliminated when the primary antibody was preincubated with the 
blocking peptide (Appendix 3). Tubulin was detected as a single band at 50 kDa. While 
ANOVA showed a tendency for EP2 levels to increase with hCG exposure (p 
value=0.07), EP2 levels increased between 0 hour and 36 hours as determined by t-test (p 
value=0.02; Figure IOC). 
EP3 was detected by immunofluorescence in granulosa cells of periovulatory 
follicles obtained 0, 12, 24, and 36 hours after hCG; EP3 was also observed in the 
ovarian stroma (Figure 91, J, K and data not shown). In the kidney, EP3 was detected in 
tubules (Figure 9L), previously reported to express this EP receptor (161, 354). EP3 
immunofluorescence was eliminated in granulosa cells when the primary antibody was 
omitted or preabsorbed with the blocking peptide (Figure 9K, L insets and data not 
shown). EP3 protein was detected in granulosa cells by western blotting as multiple 
bands, with the strongest band at 65 kDa (Figure 1 OB). All bands were absent when blots 
were probed with primary antibody preincubated with the blocking peptide (Appendix 3). 
EP3 levels increased in response to hCG, with peak levels measured in granulosa cells 
obtained 36 hours after hCG administration (Fig. 9D). EP4 protein was not detected 
EP2 
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Figure 10. EP2 and EP3 proteins in the monkey periovulatory 
follicle. Granulosa cells obtained before (0 h), 24 h, and 36 h after 
hCG administration were subjected to Western blotting for EP2 (A), 
EP3 (B) and tubulin, which was detected as a single band of 50 kDa 
in each sample. Protein levels for EP2 (C) and EP3 (D) are expressed 
relative to the tubulin content of each sample. Data are expressed as 
mean±SEM (n=3-4 animals/time point). In panel D, groups with 
different letters are different by ANOVA and Duncan's Multiple-
Range test, p value <0.05. EP2 protein was different between 0 h and 
36 h groups by 2-tailed t-test (p value=0.02). Modified from 
Markosyan et al. (376). 
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by immunofluorescence in granulosa cells of periovulatory follicles obtained 0,12,24, 
and 36 hours after hCG administration; EP4 was, however, consistently detected in the 
ovarian stroma (Figure 9M, N, O and data not shown). EP4 protein showed high levels of 
expression in kidney glomeruli (Figure 9P) as previously reported (124, 155), which 
served as a positive control. EP4 immunofluorescence was not present when the primary 
antibody was preabsorbed or omitted (Figure 90, P insets and not shown). 
Immunofluorescence on the paraffin sections of monkey ovaries obtained during 
natural menstrual cycles showed a similar pattern of EP receptor detection (Appendix 4). 
EP1 detection was absent or very low in granulosa cells of follicles obtained before or 
immediately after the ovulatory LH surge (Appendix 4A, B), but EP1 was present in 
granulosa cells of periovulatory follicles obtained on day 1 (data not shown) and day 2 
after the LH surge (Appendix 4C). EP2 and EP3 were detectable in granulosa cells of 
periovulatory follicles obtained before and after LH surge (Appendix 4D-F, G-I). EP4 
was low/nondetectable in granulosa cells at all times examined (Appendix 4J-I). These 
data demonstrate that the expression and localization of EP receptor proteins described 
above for stimulated monkey ovaries is consistent with EP localization and gonadotropin-
regulated expression as seen in ovaries obtained during natural menstrual cycles. 
Because EP4 receptors were not consistently detected in granulosa cells of ovaries 
obtained after controlled ovarian stimulation or during natural menstrual cycles, 
measurement of intracellular second messengers by granulosa cells via EP4 receptor 
stimulation was not pursued in the studies described below. 
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EP stimulation of granulosa cell cAMP generation 
To determine if stimulation of EP2 and EP3 receptors regulates cAMP levels in 
granulosa cells via interactions with Gas or Gai, cells were cultured with EP2 and EP3 
receptor agonists and antagonists. In granulosa cells obtained 24 hours after hCG, PGE2 
increased cAMP levels 5-fold above levels measured in control cells (Figure 11 A). The 
ability of PGE2 to elevate media cAMP was abolished by coincubation with the EP1/EP2 
antagonist AH6809. The EP2 agonist butaprost increased cAMP to levels intermediate 
between PGE2 and PGE2+AH6809. The EP3 agonist sulprostone did not alter granulosa 
cell cAMP levels. In the same cells, treatment with butaprost+sulprostone 
increased cAMP to levels which were not different from cAMP levels measured after 
stimulation with PGE2 (3.38±1.23 and 7.02±2.59 fold above control, respectively, n==3). 
The ability of EP agonists and antagonists to alter cAMP accumulation in 
granulosa cells obtained 36 hours after hCG was also examined. PGE2 treatment induced 
a 8-fold increase in media cAMP, which was eliminated by coincubation with AH6809 
(Figure 1 IB). Butaprost stimulated a 4-fold increase in cAMP while sulprostone doubled 
cAMP levels when compared to controls. In the same cells, treatment with 
butaprost+sulprostone yielded cAMP levels which were not different from PGE2 induced 
cAMP levels ((5.64±1.98 and 6.12±1.98 fold above control, respectively, n=3). 
EP stimulation of intracellular calcium in granulosa cells 
To determine if EP1 stimulation leads to changes in granulosa cell [Ca2+]i, 
cellular response to treatment with PGE2 or PGE2+the EP1/EP2 antagonist AH6809 was 
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Figure 11. cAMP production by monkey periovulatory granulosa 
cells. Granulosa cells were obtained from monkeys experiencing 
controlled ovarian stimulation 24 h (A) and 36 h (B) after hCG 
administration. The cells were incubated for 16 h with PGE2, PGE2 
+AH6809, butaprost, sulprostone or no treatment (control). Media 
cAMP was measured by enzyme immunoassay. For each animal, the 
cAMP level in control cells was set equal to 1.0, and the cAMP level 
in treated cells was expressed relative to the control level. Data are 
presented as mean±SEM (n=5-6 animals/time point). Within each 
panel, groups with different letters are different by ANOVA and 
Duncan's Multiple-Range test, p value<0.05. 
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assessed. Granulosa cells obtained 24 hours after hCG administration failed to increase 
[Ca2+]i in response to PCrE2 but did respond with increased fluorescence to calcimycin 
treatment (Figure 12A, B, C). In granulosa cells obtained 24 hours after hCG 
administration, treatment with PGE2 or PGE2+AH6809 did not alter [Ca2+]i when 
compared to basal levels (Figure 12G). In granulosa cells collected 36 hours after hCG, 
PGE2 treatment doubled [Ca2+]i after 20 seconds (Figure 12D, E). As anticipated, the 
increase in [Ca2+]i levels was transient and declined after the initial peak. However, by 
120 sec after treatment, [Ca2+]i levels remained elevated above the levels in the same 
cells before the treatment. EP1/EP2 antagonist AH6809 abolished the PGE2 induced 
increase in [Ca2+]i (Figure 12H). 
4.3 Discussion for Specific Aims #1 and #2 
The present study is the first to examine the expression and function of all known 
EP receptors in primate periovulatory granulosa cells. Much attention has focused on the 
identification of PGE2 as the essential ovulatory PG as well as the ability of the ovulatory 
gonadotropin surge to increase granulosa cell expression of PG synthesis enzymes, 
resulting in peak follicular PGE2 levels just before follicle rupture (51, 79, 83, 85). 
However, the data presented in this report suggest that the ovulatory gonadotropin surge 
also regulates granulosa cell responsiveness to PGE2 during the periovulatory period. 
Exposure to an ovulatory dose of hCG increased granulosa cell expression of EP1, EP2, 
and EP3 receptors as well as intracellular signal generation in response to agonist 
stimulation of these EP receptors. Taken together, these data support the hypothesis that 
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Figure 12. PGE2 regulation of [Ca2+]i in monkey periovulatory 
granulosa cells. Granulosa cells were obtained from monkeys 
experiencing controlled ovarian stimulation either 24 h (A, B, C) or 36 
h (D, E, F) after hCG administration. Cells were imaged before 
treatment (0 sec; A, D), 20 sec after PGE2 addition (B. E) and 60 sec 
after calcimycin addition (C, F). In panels A-C, arrows indicate 2 
representative cells before and after treatment. Similarly, arrows 
indicate 2 representative cells in panels D-F. Images are representative 
of 4-5 animals/time point. [Ca2+]i levels in PGE2 treated cells (filled 
circles) and AH6809+PGE2 treated cells (open circles) relative to basal 
[CaH]i level at 0 sec (represented by the horizontal line at intracellular 
calcium=l .0) are plotted for the granulosa cells obtained 24 h (G) and 
36 h (H) after hCG administration. Data are presented as mean±SEM 
(n=4-5/time point). In panel H. groups with different letters are 
different by ANOVA and Duncan's Multiple-Range test, 
p value<0.05. 
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the ovulatory gonadotropin surge regulates EP receptors to achieve peak granulosa cell 
responsiveness to PGE2 in the hours just before ovulation. In the present study, mRNA 
for EP1, EP2, EP3 and EP4 was detected in granulosa cells of monkey periovulatory 
follicles before and after hCG administration. Studies by others have shown that mRNA 
for EP1, EP2, and EP4 are expressed in either freshly isolated or long term cultured 
human luteinizing granulosa cells (127, 144); EP3 expression in human granulosa cells 
has not been reported. EP2, EP3, and EP4 mRNA are present in bovine cumulus 
granulosa cells (355, 356). Reports of sub-fertility in EP2 knockout mice (146) focused 
attention on EP2 expression and function in rodent granulosa cells (357). However, 
recent detection of EP2 and EP4, but not EP1 and EP3, mRNA in mouse granulosa cells 
supports the hypothesis that multiple EP receptors mediate the ovulatory effects of PGE2 
(143). Clearly, granulosa cell EP expression differs between species. These data, 
combined with our detection of mRNA for all EP receptors in primate granulosa cells, 
suggest that the ovulatory effects of PGE2 may require multiple EP receptors. 
The present study also demonstrated that primate granulosa cells express EP1, 
EP2, and EP3 receptor proteins. EP2 and EP3 receptors were both detected in granulosa 
cells obtained before hCG administration. In response to administration of an ovulatory 
dose of hCG, levels of EP1, EP2, and EP3 receptors increased to peak 36 hours after hCG 
administration, just before ovulation. Interestingly, EP4 protein was not detected in 
monkey granulosa cells, despite the presence of EP4 mRNA at every time examined. 
Granulosa cell EP3 mRNA and protein levels both increased in response to hCG 
administration. Although EP3 mRNA levels increased considerably 12 hours after hCG 
administration, the increase in EP3 protein expression was measured only 36 hours after 
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hCG. Levels of EP1 and EP2 proteins also increased in response to hCG, despite 
unchanged levels of their respective mRNAs. To our knowledge, this study represents the 
first report of EP receptor proteins in primate granulosa cells. Our data indicate that the 
ovulatory gonadotropin surge stimulates granulosa cell EP receptor expression to achieve 
maximal EP protein concentrations just before ovulation, when follicular PGE2 levels 
reach their peak. 
The EP receptors which mediate the ovulatory PGE2 signal in primates have not 
been identified. Mice lacking expression of EP2 have decreased ovulation and 
fertilization efficiency. In contrast, deficiencies of EP1 and EP3 expression did not 
negatively impact reproductive function (145, 146, 358, 359). In the primate 
periovulatory follicle, PGE2 begins to accumulate in follicular fluid 24 hours after hCG 
administration and reaches peak levels 36 hours after hCG, or just before ovulation (51, 
79, 85, 99). Therefore, the EP receptors involved in mediating the ovulatory PGE2 
signal should be present on granulosa cells 24-36 hours after hCG administration. The 
present study demonstrated that primate granulosa cells have EP1, EP2, and EP3 
receptors available to mediate the ovulatory effects of PGE2. Therefore, additional 
studies were performed to determine which EP receptors are functional during the 
period of elevated PGE2 which precedes primate ovulation. 
EP1 couples to Gaq to activate phospholipase C and produce inositol 
trisphosphate, which increases [Ca2+]i by release of calcium from intracellular stores 
(360). PGE2 treatment increased [Ca2+]i when granulosa cells were obtained 36 hours 
after hCG administration in vivo; granulosa cells obtained 24 hours after hCG did not 
respond to PGE2 with increased [Ca2+]i. These data are consistent with our detection of 
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EP1 protein in granulosa cells 36 h, but not 24 h, after hCG administration. The ability of 
PGE2 to increase [Ca2+]i was abolished by the EP1/EP2 receptor antagonist AH6809. It 
is unlikely that PGE2 acts via EP2 receptors to increase [Ca2+]i. EP2 receptors couple 
exclusively to Gas to increase cAMP (360, 361). While cAMP can increase [Ca2+]i via 
cyclic nucleotide gated Ca2+ channels (362), there are no reports of these channels in 
granulosa cells. Therefore, the ability of AH6809 to prevent the PGE2-stimulated 
increase in [Ca2+]i best supports the hypothesis that PGE2 increases fCa2+]i via EP1 
receptors. The presence of functional EP1 receptors only late in the periovulatory 
interval suggests that EP1 mediates at least some of the ovulatory effects of PGE2 in 
primate granulosa cells. 
EP2 couples to Gas and activates adenylyl cyclase to stimulate cAMP production 
(360). Both PGE2 and the EP2 agonist butaprost increased cAMP production by 
granulosa cells obtained 24 hours and 36 hours after hCG administration in vivo. This 
effect of PGE2 was more potent in granulosa cells obtained 36 hours after hCG; these 
cells also had the highest levels of EP2 protein. The EP1/EP2 antagonist AH6809 
reduced or abolished PGE2-stimulated cAMP production in all granulosa cell cultures 
examined. Because EP1 receptors couple exclusively to Gaq, these data support the 
conclusion that PGE2 stimulates adenylyl cyclase activity through the EP2 receptor. 
However, butaprost did not increase cAMP to the levels measured in PGE2-treated 
cultures of granulosa cells obtained 24 hours after hCG. While PGE2 may be more 
efficacious than butaprost as a ligand for the monkey EP2 receptors, PGE2 may also act 
through EP receptors in addition to EP2 to achieve maximal cAMP production. Taken 
together, our data are consistent with studies in human and rat granulosa cells (127, 143) 
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and demonstrate that primate periovulatory granulosa cells express functional EP2 
receptors. Importantly, this study is the first to demonstrate that granulosa cell response 
to EP2 receptor stimulation increases late in the periovulatory period to peak just before 
ovulation. 
EP3 receptors expressed by monkey granulosa cells couple primarily, if not 
exclusively, to Gas. Numerous isoforms of EP3 have been characterized to date (150). 
EP3 receptors which couple to God and Gaq have been reported in human cells (363). 
Our studies suggest that the EP3 receptor isoforms expressed by primate granulosa cells 
couple to Gas. The PCR primers used in this study were designed to detect all 10 known 
human EP3 mRNA splice variants, and western blotting consistently identified 3 EP3 
isoforms in monkey periovulatory granulosa cells. In granulosa cells obtained 36 hours 
after hCG administration, treatment with the EP3 receptor agonist sulprostone increased 
cAMP, suggesting that one or more EP3 receptor isoform couples to Gas. Additionally, 
sulprostone did not decrease basal or butaprost-stimulated cAMP, so it is unlikely that 
EP3 receptors couple to Gai in monkey granulosa cells. Gaq coupled EP3 receptors 
which increase [Ca2+]i were also not detected in monkey granulosa cells as the EP1/EP2 
antagonist AH6809 completely abolished the PGE2 induced increase in [Ca2+]i. 
Therefore, granulosa cells likely respond to the ovulatory gonadotropin surge with an 
increase in Gas coupled EP3 receptors, with PGE2 acting in part via EP3 receptors to 
increase cAMP production late in the periovulatory interval. 
In summary, this study is the first to demonstrate expression and function of three 
distinct EP receptors in primate periovulatory granulosa cells. Exposure of granulosa 
cells to an ovulatory dose of hCG increased levels of EP1, EP2, and EP3 receptor 
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proteins; granulosa cell responsiveness to PGE2 also increased as the expected time of 
ovulation drew near. Because each of these three EP receptors may regulate different 
intracellular events, PGE2 may utilize multiple pathways to stimulate periovulatory 
events in primate granulosa cells. The present data support the hypothesis that the 
ovulatory gonadotropin surge increases PGE2 levels within the follicle as well as the 
expression and function of EP receptors. Both PGE2 levels and EP receptor 




STUDIES FOR SPECIFIC AIMS #3 AND #4 
5.1 Materials and Methods for specific Aims #3 and #4 
Animals 
The animal husbandry, controlled ovarian stimulation and sample collection were 
performed as described for specific aims #1 and #2. Follicular aspirates were obtained 
before (0 hour) or 12, 24, or 36 hours after administration of 1000 IU r-hCG (Serono). To 
inhibit follicular PG production during the periovulatory interval, additional animals were 
treated with gonadotropins and Antide as described above; these animals also received 
the COX-2 selective inhibitor celecoxib (Celebrex, Pfizer, New York, NY) 32 mg orally 
every 12 hours beginning with hCG administration until follicles were aspirated 36 hours 
later. This treatment was previously shown to decrease follicular fluid PGE2 to very low 
levels (364). Whole ovaries were obtained from monkeys experiencing ovarian 
stimulation with or without celecoxib treatment. 
Tissue preparation 
Granulosa cell-enriched preparation and follicular fluid were obtained from 
follicular aspirates as described for specific aims #1 and #2. Granulosa cells were either 
used immediately for cell culture or were frozen in liquid nitrogen and stored at -80°C 
for preparation of total RNA. Viability of granulosa cell-enriched preparations was 
assessed by trypan blue exclusion and averaged 76%. Whole ovaries were bisected, 
maintaining at least two periovulatory follicles greater than 4 mm in diameter on each 
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piece. The pieces were covered with O.C.T. Compound (Sakura, Tokyo, Japan), frozen in 
liquid propane, and stored at -80°C. 
Granulosa cell culture 
Monkey granulosa cells obtained before hCG administration were plated on 
LabTek glass chamber slides (Nalgene Nunc, Rochester, NY) at a concentration of 
20.000 cells/200 ui medium or 48 well culture plates (Corning Incorporated, Corning, 
NY) at a concentration of 100,000 cells/400 ul medium. The cells were cultured on 
fibronectin-coated surfaces in serum-free DMEM-Ham's F12 medium containing insulin, 
transferrin, selenium, aprotinin, and human low-density lipoprotein as previously 
described in Materials and Methods for specific aims #1 and #2. At the initiation of 
culture, hCG (Serono; 100 ng/ml) and indomethacin (Sigma Chemical Co., St Louis, 
MO; 100 nM) were added to all except the control wells. After 24 hours in vitro, one of 
the following treatments was added: PGE2 (1 uM), the EP1 agonist 17 phenyl-trinor 
PGE2 (10 uM), the EP2 agonist butaprost (10 uM), or the EP3 agonist sulprostone (1 
uM). PGE2 and all EP receptor selective agonists were obtained from Cayman Chemicals 
(Ann Arbor, MI). Cells were then maintained in vitro for an additional 4 or 12 hours, 
after which the cells were either lysed with Trizol reagent (Invitrogen, Rockville, MD) 
for RNA extraction or fixed with 10% buffered formalin for 30 minutes then stored at 
4°C in PBS for immunofluorescent detection of tPA and PAI-1 proteins. For the same 
purpose, some cells were cultured with or without 20 IU/ml hCG (Sigma) alone for 12, 
24 and 36 hours, then formalin fixed. Additional granulosa cells were cultured on 
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chamber slides with hCG+indomethacin for 24 or 36 h, then fixed and stored as described 
above for immunofluorescent detection of EP receptors. 
Real-Time RT-PCR 
Levels of mRNA for tPA, uPA, and PAI-1 were assessed by real-time RT-PCR 
using a Roche LightCycler (Roche Diagnostics, Indianapolis, IN, USA). Total RNA was 
obtained from granulosa cells using Trizol reagent, treated with DNase and reverse 
transcribed. PCR was performed using the FastStart DNA Master SYBR Green I kit 
(Roche) following manufacturer's instructions and using 0.5 uM primers and 4 mM 
MgCb. Primers were designed using LightCycler Probe Design software (Roche) based 
on the human or monkey sequences (Table 2) and span an intron to prevent undetected 
amplification of genomic DNA. PCR products were sequenced (Microchemical Core 
Facility, San Diego State University, CA) to confirm amplicon identity. At least 5 log 
dilutions of the sequenced PCR product were included in each assay and used to generate 
a standard curve. For each sample, the content of tPA, uPA, PAI-1, and P-actin mRNA 
was determined in independent assays. No amplification was observed when monkey 
cDNA was omitted. All data were expressed as the ratio of mRNA of interest to P-actin 
mRNA for each sample. 
Immunofluorescent protein detection 
Frozen ovarian tissues were sectioned at 10 urn and fixed with buffered 10% 
formalin. After antigen retrieval with 10 mM sodium citrate, sections were blocked with 
5% non-immune goat serum (Vector Laboratories) in PBS containing 0.1% Triton. 
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Sections were then incubated for 1 hour at room temperature either with primary 
antibody generated against tPA (rabbit anti-human polyclonal antibody at 4 ug/ml, Santa 
Cruz Biotechnologies, Santa Cruz, CA), uPA (mouse anti-human monoclonal antibody, 
15 ug/ml, Calbiochem), PAI-1 (mouse anti-human monoclonal antibody, 10 |u,g/ml, 
Calbiochem), or no primary antibody, followed by incubation with Alexa Fluor 488 
conjugated anti-rabbit or anti-mouse secondary antibody (4 ug/ml; Molecular Probe After 
incubation with 1% Sudan Black in 70% methanol, the slides were coverslipped using 
Vectashield medium (Vector Laboratories). 
Formalin-fixed cultured granulosa cells were blocked with 5% non-immune goat 
serum and incubated for 1 hour at room temperature with either the tPA or PAI-1 primary 
antibody and Alexa Fluor 488 secondary antibody as described above. Additional 
formalin-fixed cultured granulosa cells were blocked with 5% non-immune goat serum 
and incubated for 1 hour at room temperature with a rabbit anti-human polyclonal 
antibody against one of the following PGE2 receptors: EP1 (2 ug/ml), EP2 (10 ug/ml), or 
EP3 (4 ug/ml); all EP receptor antibodies were obtained from Cayman Chemical. In 
some experiments, the anti-EP receptor primary antibody was preincubated with the 
respective blocking peptide at a 1:2 ratio prior to use in the primary antibody incubation 
step. Immunofluorescent protein detection proceeded as described above. 
All images were obtained using an Olympus BX41 fluorescent microscope fitted 
with a DP70 digital camera and associated software (Olympus, Melville, NY). 
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In situ zymography 
PA activity was detected using modifications of previously reported methods 
(365, 366). 10 jam thick frozen ovarian sections were rapidly thawed at 37°C and stained 
with propidium iodide (100 ng/ml; Sigma-Aldrich, St. Louis, MO) in PBS for 1 minute. 
Carnation nonfat milk powder (Nestle, Glendale, CA) was dissolved in PBS (20% w/v), 
heated to 95 °C for 30 minutes and centrifuged for 5 minutes at 3000g. The supernatant 
was maintained at 55°C. A 1.2% solution of agar in water was boiled for 10 minutes then 
chilled to 55°C. Four parts of 1.2 % agar were mixed with one part of milk solution, and 
plasminogen (75 u.g/ml; Molecular Innovations, Inc, Southfield, MI) was added. Tissue 
sections were overlaid with the agar-milk-plasminogen mixture, coverslipped, and 
incubated at 37°C in humidified chamber for 90 minutes. Proteolytic areas appeared as 
clear, transparent zones in the opaque and cloudy overlay mixture. Ovarian sections were 
then stored at 4°C until images were taken. Dark-field and fluorescent images were 
obtained using an Olympus BX41 fluorescent microscope as described above. 
To determine whether plasminogen was required for proteolysis, some ovarian 
sections were overlaid with an agar-milk mixture lacking plasminogen. Additional 
ovarian sections were pre-incubated with the anti-tPA antibody (8 ng/ml) for 10 minutes 
at room temperature, after which in situ zymography was performed as described above. 
In the preliminary experiments, proteolysis was monitored periodically every 30 min for 
4 hours, then at 5, 7, and 20 hours in order to determine the optimal incubation time. 
Proteolysis over areas containing cells was apparently complete by 90 minutes, so all data 
were collected after 90-minute incubation. After 3-hour incubation, proteolytic zones 
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were visible distant from the tissue section, indicating spontaneous degradation of milk 
casein. 
tPA and PAI-1 measurements in follicular fluid 
Follicular fluid levels of total tPA and total PAI-1 were determined using 
AssayMax Human tPA and AssayMax Human PAI-1 ELISA kits (AssayPro, St. Charles, 
MO) according to the kit instructions. Intra-assay coefficients of variation for tPA and 
PAI-1 kits were 5.7 % and 4.7 % respectively; all samples were tested within one tPA or 
PAI-1 assay. The lower limit of detection (0.031 ng/ml for tPA) was used for statistical 
analysis of one granulosa cell sample obtained at 0 hour hCG as tPA was not detectable 
by ELISA. 
Data analysis 
All data were assessed for heterogeneity of variance and were log-transformed 
when Bartlett's test yielded a significance of less than 0.05. Data presented in Figures 
12A-C and 14B were log-transformed before further analysis. In all figures, 
untransformed data are presented. Data presented in Figures 12 and 14 were assessed by 
ANOVA. Levels of tPA and PAI-1 mRNA in cultured granulosa cells were assessed by 
ANOVA with one repeated measure. For all ANOVAs, posthoc analyses were performed 
using Duncan's multiple range test. Statistical analyses were performed using StatPak 
v4.12 software (Northwest Analytical, Portland, OR). Data are presented as mean ± 
SEM, and significance was assumed at p value < 0.05. 
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5.2 Results for Specific Aims #3 and #4 
tPA, uPA and PAI-1 expression in granulosa cells 
Monkey granulosa cells expressed mRNA for tPA, uPA and PAI-1 before and 
after administration of an ovulatory dose of hCG in vivo (Figure 13). Levels of tPA 
mRNA were not different 0-24 hours after hCG administration, but tPA expression 
decreased 36 hours after hCG to levels below those measured after 12 hours of hCG 
exposure (Figure 13 A). Levels of uPA mRNA levels were low at 0 hour hCG, increased 
transiently 12 hours after hCG administration, and returned to low levels 36 hours after 
hCG administration (Figure 13B). PAI-1 mRNA was low at 0 hour hCG, increased 12 
hours after hCG administration, and remained high for the rest of the periovulatory 
period, peaking 36 hours after hCG administration (Figure 13C). The ability of hCG-
stimulated PGs to modulate expression of PA family members was also examined. 
Administration of the PG synthesis inhibitor celecoxib with hCG for 36 hours did not 
alter mRNA levels for tPA, uPA, or PAI-1 when compared with mRNA levels after 
treatment with hCG alone (Figure 13). Therefore, an ovulatory dose of hCG regulated 
granulosa cell levels of mRNA for these PA family members, but hCG-stimulated PGs 
did not alter expression of PA family members. 
PA family member proteins were localized to monkey ovarian cells using 
immunofluorescence. Before hCG administration, tPA protein levels were very low in 
both granulosa cells and in the ovarian stroma (Figure 14A). After treatment with hCG 
for 12, 24 or 36 hours, tPA protein was easily detected in the cytoplasm of granulosa cells 
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Figure 13. tPA, uPA, and PAI-1 mRNA levels in monkey granulosa cells. 
Granulosa cells were obtained from monkeys experiencing controlled ovarian 
stimulation before (0 hour) and 12, 24, and 36 hours after hCG administration; 
additional animals received hCG and celecoxib (36+cbx) for 36 hours. 
Granulosa cell levels of mRNAs were determined by real time RT-PCR; all 
mRNA levels are expressed relative to P-actin mRNA. Data are presented as 
mean±SEM (n=4-6 animals/time point). In panels A, B, and C, groups with 
different letters are different by ANOVA and Duncan's, 
pvalue<0.05. 
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Figure 14. Detection of tPA and PAI-1 proteins and PA proteolytic activity in the 
monkey periovulatory follicles. Ovaries were obtained from monkeys experiencing 
controlled ovarian stimulation as described in the legend for Figure 1. 
Immunodetection (bright green) of tPA (A-E) and PAI-1 (F-J) is shown after 
treatment with hCG for 0 (A, F), 12 (B, G), 24 (C, H), or 36 (D, I) hours, or with 
hCG+celecoxib for 36 hours (E, J). Sections are not counterstained. For panels A-
J, use bar in panel E=100 um. There was no detectable immunofluorescence when 
the primary antibody for tPA (D inset) or PAI-1 (I inset) was omitted. In situ 
zymography was performed using ovarian sections obtained after treatment with 
hCG for 0 (K), 12 (L), 24 (M), or 36 (N) hours, or with hCG+celecoxib for 36 
hours (O). In all panels, propidium iodide staining of cell nuclei appears red. 
Undegraded casein protein is detectable as greenish cloudy spots; casein is absent 
in the areas of proteolysis (black or spot-free areas indicated by white arrows). No 
proteolysis was observed when plasminogen was omitted from the overlay mixture 
(P) or when tissues were pre-incubated with the anti-tPA antibody (Q). Milk casein 
was captured on dark field images whereas cell nuclei were visible under the 
fluorescent light. All panels are composites of dark field and fluorescent images of 
ovarian sections. In each periovulatory follicle shown, the antrum (a) is in the 
upper right, granulosa cells (gc) are central, and the ovarian stroma (s) is in the 
lower left portion of the image. For panels K-Q, bar in panel 0=400 um. All 
ovarian images, except panels P and Q, are representative of 3 animals/time point. 
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and, to a lesser extent, in the ovarian stroma (Figure 14B-D). uPA protein was low to 
undetectable in granulosa cells and the ovarian stroma at all times examined (Appendix 6 
and data not shown). However, uPA was present in the endothelial cells of large blood 
vessels located in the ovarian stroma and in kidney, which served as a positive control. 
PAI-1 protein was low to undetectable in granulosa cells and the ovarian stroma 
before hCG administration (Figure 14F). However, PAI-1 protein was easily detected in 
the cytoplasm of granulosa cells of ovaries obtained 12, 24 and 36 hours after hCG 
administration (Figure 14G-I). Treatment with hCG+celecoxib for 36 hours reduced both 
tPA and PAI-1 proteins to very low levels when compared with tPA and PAI-1 protein 
detection in granulosa cells of monkeys treated with hCG only (Figure 14E, J). 
Immunofluorescence was absent when the primary antibodies for tPA and PAI-1 were 
omitted, serving as a negative control (Figure 14D, I insets). Therefore, tPA and PAI-1, 
but not uPA, proteins were present in the granulosa cells of monkey periovulatory 
follicles. Levels of tPA and PAI-1 protein increased in response to an ovulatory dose of 
hCG, but continued expression was eliminated by the PG synthesis inhibitor celecoxib. 
To confirm that hCG upregulates granulosa cell expression of tPA and PAI-1 
proteins, granulosa cells obtained before hCG administration were cultured without 
(control) or with an ovulatory dose of hCG for 12, 24 and 36 hours. tPA 
immunodetection was very low in controls (Appendix 6A-C) but increased tPA protein 
expression was present in the cells that were treated with hCG for 12, 24 and 36 hours 
(Appendix 6D-F). Similarly, hCG increased PAI-1 protein expression over the controls at 
all times examined (Appendix 6G-L). 
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In situ Zymography for PA activity in the monkey periovulatory follicle 
Detection of PA activity utilized the concept that PA family members convert 
inactive plasminogen to the active protease plasmin, which can digest the milk protein 
casein. To identify regions of ovarian follicles that contained PA activity, tissue sections 
were overlaid with a mixture containing both plasminogen and casein. Intact casein 
appeared as a greenish cloudy or spotty substance (Figure 14K); proteolysis was detected 
as dark regions which were cleared of the cloudy or spotty material (Figure 14L-N). 
Omission of plasminogen from the overlay mixture deprived the reaction of this essential 
proenzyme, and no proteolysis was observed (Figure 14P), demonstrating that this 
technique specifically detected PA-dependent proteolytic activity. 
Ovarian tissues obtained before administration of an ovulatory dose of hCG did 
not contain sufficient PA proteolytic activity to degrade the casein present in the overlay 
mixture (Figure 14K). In contrast, vast zones of proteolysis were observed over and 
around granulosa cells of ovaries obtained 12, 24, and 36 hours after hCG (Figure 14L-
N). Proteolytic activity was absent over ovarian sections obtained from animals treated 
for 36 hours with hCG and celecoxib (Figure 140). Importantly, pre-incubation of tissue 
sections with the anti-tPA antibody essentially eliminated proteolysis around granulosa 
cells (Figure 14Q), supporting the conclusion that PA activity in monkey periovulatory 
follicle is catalyzed mainly by tPA. Therefore, exposure to an ovulatory dose of hCG 
increased granulosa cell tPA activity, and this increase in PA activity in the late 
periovulatory period was dependent on ovarian PG production. 
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tPA and PAI-1 protein levels in follicular fluid 
Secreted tPA and PAI-1 were examined by assessment of PA family members in 
monkey follicular fluid. Levels of tPA in follicular fluid were low before hCG, increased 
to reach peak levels 24 hours after hCG administration, and returned to intermediate 
levels 36 hours after hCG (Figure 15A). PAI-1 levels in follicular fluid were low before 
hCG, increased 12 hours after hCG administration, and remained high for the rest of the 
periovulatory period (Figure 15B). Therefore, levels of tPA and PAI-1 proteins in 
follicular fluid increased in response to hCG administration, similar to hCG-regulated 
changes in tPA and PAI-1 proteins detected in granulosa cells by immunofluorescence. 
tPA and PAI-1 protein expression in cultured granulosa cells 
Inhibition of PG synthesis within the periovulatory follicle prevented follicle 
rupture, while intrafollicular injection of PGE2 restored follicle rupture in inhibitor-
treated monkeys (96). PGE2 levels in monkey follicular fluid were very low 0 and 12 
hours after hCG administration; PGE2 levels increased 24 hours after hCG and peaked at 
36 hours after hCG (99). Therefore, key actions of PGE2 are anticipated to occur late in 
the periovulatory interval. While celecoxib treatment in vivo reduces intrafollicular PGE2 
levels (364), this COX-2 inhibitor likely blocks production of many eicosanoids within 
the monkey follicle. Further experiments were necessary to identify the unique role of 
PGE2 in the regulation of granulosa cell tPA and PAI-1 expression. 
To determine if hCG alone or hCG-stimulated PGE2 regulates granulosa cell tPA 
and PAI-1 expression, a cell culture model was developed to mimic in vivo periovulatory 
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Figure 15. tPA and PAI-1 protein levels in follicular 
fluid. Aspiration of follicular fluids was performed 
on monkeys experiencing controlled ovarian 
stimulation before (0) and 12, 24, and 36 hours after 
hCG administration. tPA and PAI-1 proteins were 
measured by ELISA. Data are presented as 
mean±SEM (n=4-5 animals/time point). In panels A 
and B, groups with different letters are different by 
ANOVA and Duncan's, p value<0.05. 
107 
events (Figure 16). Cells obtained from large, preovulatory follicles before hCG were 
maintained in vitro with an ovulatory dose of hCG; the general COX inhibitor 
indomethacin was also included in culture medium to inhibit endogenous PG production. 
After 24 hours of culture, PGE2 (or an EP receptor selective agonist) was added to some 
cultures to simulate the rise in follicular fluid PGE2 which occurs 24 hours after hCG 
administration in vivo. Cells were then cultured for an additional 4 or 12 hours, for a total 
of 28 or 36 hours in vitro, to examine the effects of short-term or long-term PGE2 
exposure, respectively. 
Granulosa cells cultured for a total of either 28 and 36 hours with no treatment 
(control), hCG+indomethacin, hCG+indomethacin+PGE2, or hCG+indomethacin+an EP 
receptor selective agonist were assessed for tPA and PAI-1 mRNA levels (Appendix 7). 
Neither tPA nor PAI-1 mRNA levels differed between treatment groups at either time 
examined. This is similar to our findings obtained from monkey granulosa cells treated 
with hCG alone or hCG+celecoxib in vivo, where no differences were observed between 
tPA or PAI-1 mRNA levels in granulosa cells obtained late in the periovulatory interval 
in the absence or presence of this PG synthesis inhibitor (Figure 13). 
Protein expression of tPA was assessed by immunofluorescence in granulosa cells 
cultured as described above. Granulosa cells cultured for 28 hours with no treatment 
(Figure 17 A) or with hCG+indomethacin (Figure 17B) showed very low levels of tPA 
protein. In granulosa cells that received PGE2 for the final 4 hours during a total of 28 
hours in vitro with hCG+indomethacin (Figure 17C), tPA protein was apparently more 
abundant. tPA protein detection was very low in granulosa cells that received EP1 
receptor agonist 17 phenyl-trinor PGE2 instead of PGE2 (Figure 17D). In contrast, 
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Figure 16. Cell culture model to mimic in vivo periovulatory 
events. Cells obtained from large, preovulatory follicles before 
hCG were maintained in vitro either with no treatment (Control) 
or with an ovulatory dose of hCG plus the general COX inhibitor 
indomethacin included in culture medium to inhibit endogenous 
PG production (hCG+lndomethacin). After 24 hours of culture, 
PGE2 or an EP receptor selective agonist was added to some 
cultures (hCG+Indomethacin+PGE2 or EP agonist) to simulate 
the rise in follicular fluid PGE2, which occurs 24 hours after hCG 
administration in vivo. Cells were harvested after additional 4 or 
12 hours of culture, for a total of 28 or 36 hours in vitro, to 
examine the effects of short-term or long-term PGE2 exposure, 
respectively. 
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Figure 17. Immunofluorescent detection of tPA and PAI-1 
proteins in cultured granulosa cells. Granulosa cells obtained 
from animals undergoing controlled ovarian stimulation before 
hCG administration were maintained in vitro with no treatment 
(A, G) or with hCG+indomethacin (B-F, H-L). After 24 hours, 
some cultures received additional treatment: PGE2 (C, I), 17 
phenyl-trinor PGE2 (D, J), butaprost (E, K), or sulprostone (F, 
L). Cells were cultured for a total of 28 hours for 
immunodetection of tPA (A-F) or 36 hours for 
immunodetection of PAI-1 (G-L). Immunodetection appears 
green; nuclei are counterstained red. All images are 
representative of 4 animals/treatment. For all images, use bar in 
panel A=20 urn. 
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intense tPA immunofluorescence was present in granulosa cells treated with either the 
EP2 receptor agonist butaprost or the EP3 receptor agonist sulprostone (Figure 17E, F). 
PGE2, butaprost, and sulprostone (but not 17 phenyl-trinor PGE2) also increased 
immunofluorescent detection of tPA protein in granulosa cells cultured for a total of 36 
hours (data not shown). 
PAI-1 protein was low/non detectable in granulosa cells cultured for 28 hours 
with no treatment, hCG+indomethacin, hCG+indomethacin+PGE2, or 
hCG+indomethacin+any EP receptor selective agonist (data not shown). Cells cultured 
for 36 hours with no additional treatment (Figure 17G) or with hCG+indomethacin 
(Figure 17H) showed very low levels of PAI-1 protein. PAI-1 immunofluorescence was 
more abundant in granulosa cells that received PGE2 during the final 12 hours during a 
total of 36 hours in vitro (Figure 171). Treatment with either the EP1 receptor agonist 17 
phenyl-trinor PGE2 or the EP3 receptor agonist sulprostone increased PAI-1 
immunofluorescence (Figure 17J, L), similar to PAI-1 levels observed in granulosa cells 
treated with PGE2. In contrast, PAI-1 immunofluorescence was very low or absent in 
granulosa cells treated with the EP2 receptor agonist butaprost (Figure 17K). Neither tPA 
nor PAI-1 was detected when the primary antibody was omitted (data not shown). 
To determine if EP receptors were available to mediate the effects of PGE2 or EP 
receptor selective agonists in vitro, immunofluorescent detection of EP receptor proteins 
was performed. EP1, EP2, and EP3 proteins were present in granulosa cells cultured with 
hCG+indomethacin for 24 and 36 hours (Appendix 8A-C and data not shown). No EP 
receptor immunostaining was observed when the primary antibodies were pre-incubated 
with the respective blocking peptide (Appendix 8D-F). 
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5.3 Discussion for Specific Aims #3 and #4 
This study is the first to demonstrate that gonadotropin regulation of PA activity 
in the periovulatory follicle is mediated via PGE2. In vivo, granulosa cell tPA and PAI-1 
protein expression as well as PA proteolytic activity increased in response to 
administration of an ovulatory dose of gonadotropin. However, maintenance of tPA and 
PAI-1 protein levels as well as PA activity requires PG synthesis in the late periovulatory 
period. PGE2 has previously been identified as the key PG involved in ovulation in many 
species (41, 367), including monkeys (96). While defects in follicle rupture consistently 
occur when follicular PG synthesis is inhibited, the specific mechanism by which 
elevated intrafollicular PGE2 promotes ovulation is unknown. This investigation presents 
novel data which demonstrate that PGs are required to maintain PA proteolytic activity 
late in the periovulatory interval. Granulosa cell levels of tPA and PAI-1 are regulated via 
PGE2 (EP) receptors, confirming that PGE2 is involved in periovulatory regulation of PA 
family components. Different EP receptors mediate the ability of PGE2 to regulate 
expression of tPA and PAI-1. EP receptor selective agonists and antagonists may be 
useful to promote or inhibit follicular proteolysis by independently controlling the 
expression and activities of members of the PA system. 
Expression of the components of the PA system increased in response to the 
ovulatory gonadotropin surge. In the present study, we used a combination of techniques 
to demonstrate that hCG increased levels of tPA and PAI-1 proteins in both granulosa 
cells and follicular fluid in monkey periovulatory follicles. Previous studies focused on 
measurement of secreted PA family member proteins (216, 309. 318, 319, 322, 368). 
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Follicular fluid and conditioned media from cultures of follicular cells and were assessed 
for levels of PA family member proteins, but gonadotropin regulation of synthesis of PA 
family member proteins in vivo was not directly addressed (216, 309, 318, 322, 368). In 
the present study, granulosa cells were identified as the primary site of tPA and PAI-1 
synthesis in periovulatory follicles of cynomolgus macaques. These findings contrast 
with a report identifying theca, but not granulosa, cells as the primary site of PAI-1 
synthesis in the rhesus monkey follicle (319). However, this study relied on primary 
cultures of theca and granulosa cells and did not confirm the presence of PAI-1 protein in 
specific cell types in ovarian tissue sections. While tPA was consistently detected in 
monkey follicles, uPA protein was not detected, despite the presence of uPA mRNA in 
monkey granulosa cells. The presence of uPA in the endothelium of the ovarian blood 
vessels suggests a possible role in vascular remodeling, but tPA is likely the predominant 
PA enzyme involved in proteolysis of the follicle wall. While previous studies focused 
on the ability of the ovulatory gonadotropin surge to increase levels of secreted proteins, 
the present study demonstrates that hCG increases granulosa cell tPA and PAI-1 protein 
levels, implicating hCG as a primary stimulus for synthesis of these important proteins. 
Earlier studies have shown that gonadotropin regulates mRNA levels of PAs and 
their inhibitors in ovarian follicles (312, 318, 369, 370). Although human periovulatory 
granulosa cells were shown to express abundant amounts of PAI-1 mRNA but not mRNA 
for tPA or uPA (371), our study used more sensitive RT-PCR to detect measurable tPA, 
uPA and PAI-1 mRNA in monkey granulosa cells obtained throughout the periovulatory 
period. In addition, human granulosa cells were collected from women undergoing in 
vitro fertilization, so aspirates were collected only late in the periovulatory period when, 
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as we have shown, uPA and tPA mRNAs are very low while PAI-1 mRNA expression 
was highest. Most importantly, mRNA levels for tPA and PAI-1 did not correlate with 
changing protein levels in the present study, suggesting that the expression of PA family 
members is regulated primarily at a post-transcriptional level. Assessment of protein 
levels and, ideally, activity will be required to understand how PA family members are 
regulated and how these key proteins contribute to proteolytic events necessary for 
ovulation. 
The ovulatory gonadotropin surge induced changes in proteolytic activity in the 
follicle wall during the periovulatory period. In situ zymography was used to demonstrate 
the presence of proteolytic activity primarily around granulosa cells in monkey 
periovulatory follicles. Omission of plasminogen confirmed that the observed proteolysis 
was mediated by a member of the PA family. Proteolysis detected by in situ zymography 
correlated with levels of tPA protein observed in granulosa cells by immunofluorescence, 
with little protein or proteolysis observed in ovaries obtained before (0 hour) hCG and 
abundant protein and proteolysis observed at all times after hCG administration. 
Pretreatment of ovarian tissues with an anti-tPA antibody essentially eliminated 
plasminogen-dependent proteolytic activity around granulosa cells, again supporting 
identification of tPA, but not uPA, as the active PA in the periovulatory follicle. Previous 
studies provide indirect evidence of tPA regulation by gonadotropins. In rat and monkey 
granulosa cells, gonadotropin exposure in vivo increased tPA activity in conditioned 
medium obtained from granulosa cell cultures (216, 319). Perhaps most interesting is a 
study by Dow and colleagues, where the apex and base of periovulatory follicles were 
dissected free, and homogenates were subjected to gel zymography for tPA and uPA 
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activity (372). While an ovulatory dose of gonadotropin increased tPA and uPA activity 
in both apical and basal homogenates, similar levels of proteolytic activity were 
measured in these regions, suggesting that PA-mediated proteolysis is not restricted to the 
follicle apex and may occur around the entire perimeter of the follicle at ovulation. Work 
by Murdoch and colleagues has suggested that the ovarian surface epithelium secretes 
uPA via the basolateral membrane (373), so PA activity provided by the surface 
epithelium may well determine the actual location of the follicle apex via PA proteolytic 
activity. The presence of PA-mediated proteolysis around the entire follicle also suggests 
that the PA system may be involved in the structural remodeling and neovascularization 
necessary for both ovulation and corpus luteum formation. 
In situ zymography showed that the gonadotropin-stimulated increase in tPA 
activity occurred despite the concomitant increase in the PAI-1 protein expression. In our 
cynomolgus macaques, PAI-1 protein was present at low levels in ovaries obtained 
before hCG; PAI-1 protein was easily detected in granulosa cells at all times after hCG 
administration. Plasminogen- and tPA-dependent proteolysis began as early as 12 hours 
after hCG administration and continued throughout the periovulatory period, so hCG 
administration increased follicular tPA activity in parallel with rising tPA and PAI-1 
proteins. As a member of the serpin family, PAI-1 inhibits PA activity by mimicking the 
substrate and trapping the enzyme in an inactive stable 1:1 complex (285). The observed 
gonadotropin-stimulated increase in proteolytic activity indicates that at least a portion of 
the tPA induced by gonadotropin stimulation was unopposed by PAI-1. Parallel 
regulation of a proteolytic enzyme and its inhibitor as described in this study has also 
been reported for matrix metal!oproteases and their tissue inhibitors (225, 248, 279). This 
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type of parallel regulation may prevent uncontrolled proteolysis by limiting the site 
and/or extent of proteolytic degradation. 
Evidence from several studies supports the hypothesis that gonadotropin 
regulation of PA-mediated proteolysis in the follicle requires ovarian PG synthesis. 
Studies in rat have shown that in vitro the general COX inhibitor indomethacin inhibits 
gonadotropin-stimulated granulosa cell fibrinolytic activity, while PGs alone or in 
combination with LH induce fibrinolytic activity in granulosa cell conditioned media 
(216, 309, 322, 374). The activity of tPA, as measured by gel zymography in follicular 
fluid and homogenates of ovarian follicular apex tissue, was inhibited by indomethacin 
treatment in the cow (318). While these studies support a role for COX-mediated PG 
synthesis to regulate PA family member proteins and PA-mediated proteolytic activity in 
ovarian tissues, the specific PG involved has not been identified. 
Our in vitro studies support the hypothesis that PGE2 is the biologically active 
prostanoid important for the maintenance of ovulatory PA activity. In the non-human 
primate, PGE2 levels increase 24 hours after hCG administration and peak just before the 
expected time of ovulation (99). In vivo, elevated PGE2 levels in the late periovulatory 
period maintained tPA and PAI-1 expression and PA proteolytic activity, whereas PG 
synthesis inhibition with celecoxib greatly inhibited the expression of PA family member 
proteins as well as tPA dependent proteolytic activity. For in vitro studies, cultures of 
granulosa cells were treated to simulate this window of PGE2 exposure, which occurs 
late in the periovulatory period in vivo. To inhibit the production of all bioactive PGs in 
granulosa cell cultures, indomethacin was included with an ovulatory dose of hCG; 24 
hours later, PGE2 or an EP receptor selective agonist was added to examine the effect on 
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the expression of tPA and PAI-1. Similar to in vivo results, hCG alone was not able to 
maintain granulosa cell levels of tPA and PAI-1 proteins after 28 or 36 hours in vitro. In 
contrast, PGE2 maintained tPA and PAI-1 protein levels, confirming a key role for this 
specific prostanoid in plasminogen dependent proteolysis in the follicle wall. 
Perhaps the most important and novel result of our in vitro studies was the 
demonstration that different subsets of PGE2 receptors were required to maintain tPA and 
PAI-1 protein expression. PGE2 can act through 4 G protein coupled receptors: EP1, 
EP2, EP3, and EP4 (360, 375). In a previous study, we demonstrated that monkey 
granulosa cells express functional EP1, EP2, and EP3 receptors; granulosa cell 
expression and responsiveness of all three EP receptors peaked just before the expected 
time of ovulation (376). In order to identify the EP receptors through which PGE2 
regulates PA components, EP receptor selective agonists were used to stimulate 
individual EP receptors in granulosa cell cultures. Activation of EP2 and EP3 receptors 
increased tPA protein levels. Both EP2 and EP3 can increase intracellular cAMP by 
coupling to Gas (148), suggesting a common mechanism of action to regulate granulosa 
cell levels of tPA protein. In contrast, PAI-1 protein expression was increased by 
stimulation of EP1 and EP3 receptors, each of which can couple to Gaq to regulate 
additional intracellular signaling pathways (114). Further studies will be required to 
identify the specific intracellular signaling pathways responsible for regulation of tPA 
and PAI-1 expression. These novel studies indicate that tPA and PAI-1 expression and 
activity can be independently regulated via different PGE2 receptors. Therefore, drugs 
which bind to a single EP receptor may be useful to selectively stimulate proteolysis of 
the follicle wall via EP2 or selectively inhibit follicular proteolysis via EP1. By 
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identifying EP receptors which regulate specific proteins involved in ovarian proteolysis, 




High intrafollicular PGE2 levels right before expected time of ovulation and the 
inability of follicles to rupture and release the oocyte in the absence of PG synthesis led 
to the hypothesis that PGE2 plays an essential ovulatory role in the late periovulatory 
period, most probably to facilitate the proteolytic degradation of the follicle wall. To 
elucidate the role of PGE2 in primate ovulation, the expression and function of EP 
receptors as well as their involvement in the regulation of the components of PA/plasmin 
system were studied in primate periovulatory granulosa cells. 
From these studies the following conclusions were made: 
Specific Aim #1: Three out of four EP receptors (EP1, EP2, and EP3) are expressed in 
periovulatory granulosa cells. The expression of these receptor proteins is regulated by 
the ovulatory gonadotropin surge to achieve peak EP receptor levels before the expected 
time of ovulation. 
Specific Aim #2: In the late periovulatory period, the ability of EP2 and EP3 receptors to 
stimulate cAMP production and the ability of the EP1 receptor to increase [Ca2+]i are 
increased in response to an ovulatory dose of gonadotropin, such that maximal second 
messenger generation occurs with peak follicular PGE2 levels. 
Specific Aim #3: The ovulatory gonadotropin surge induces plasminogen dependent 
proteolysis in the primate periovulatory follicle. However, late in the periovulatory 
period, hCG alone is unable to maintain the maximal proteolytic activity required for the 
degradation of follicle wall. In the final hours proceeding ovulation, PGs are necessary 
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for the expression of tPA and PAI-1 proteins and, hence, for the maintenance of 
plasminogen dependent proteolysis. 
Specific Aim #4: Experiments on the cultured granulosa cells show that PGE2, acting via 
different EP receptor subsets, regulates the expression of tPA and PAI-1 proteins. The 
data supports the hypothesis that one specific ovulatory action of PGE2 is to facilitate 
proteolytic degradation of the follicle wall. 
Identification of PGE2 and the specific EP receptors involved in the regulation of 
ovarian proteolysis provides new targets for the development of drugs to promote 
ovulation and treat some cases of infertility, or to prevent ovulation and achieve 
contraception without alteration of circulating levels of ovarian steroid hormones. 
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Figure 18. cAMP production by monkey periovulatory granulosa 
cells in response to treatment with different doses of PGE2. 
Granulosa cells were obtained from monkeys experiencing 
controlled ovarian stimulation 36 hours after hCG administration and 
plated 20,000 cells/well in 200 ul medium. The cells were incubated 
for 16 hours with no PGE2 (0) or with PGE2 at 0.01 uM, 0.1 uM, 
and 1 uM concentrations (n=2). Media cAMP was measured by 
enzyme immunoassay and normalized to the protein content of the 
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Figure 19. cAMP accumulation in 
granulosa cell culture media in response 
to PGE2 treatment. Granulosa cells 
were obtained from monkeys 
experiencing controlled ovarian 
stimulation 24 (n=l) or 36 (n=2) hours 
after hCG administration and plated 
20,000 cells/well in 200 ul medium. 
The cells were incubated with PGE2 for 
4, 10, 16, and 24 hours. Media cAMP 
was measured by enzyme immunoassay 
and normalized to the protein content of 
the well. Data are presented as 




5 0 k D a ' " SO kDa 
10 11 12 13 
Anti-EP2 Anti-EP2 Anti-EP3 Anti-EP3 
antibody antibody+ antibody antibody+ 
blocking peptide blocking peptide 
Figure 20. Western blotting for EP2 and EP3 receptors with primary 
antibodies pre-incubated with antibody blocking peptides. Lysates containing 
20 ug of protein from monkey periovulatory granulosa cells (lanes 1, 4, 8, 
and 11), human periovulatory granulosa cells (lanes 2, 5, 9, and 12), and 
monkey kidney (lanes 3, 6, 10, and 13) were analyzed by western blotting. 
Membranes were incubated with antibodies against EP2 (lanes 1, 2, and 3) 
and EP3 (lanes 8, 9, 10), or with anti-EP2 antibody+blocking peptide (lanes 
4, 5, 6) and anti-EP3 antibody+blocking peptide (lanes 11, 12, 13). For lanes 
4-6 and 11-13 anti-EP2 and anti-EP3 antibodies were pre-incubated with 
respective blocking peptides in 1:2 ratio for 1 hour at room temperature. 
APPENDIX 4 
Figure 21. Immunofluorescent detection of EP receptors in 
monkey granulosa cells. Ovaries were obtained from monkeys 
experiencing spontaneous menstrual cycles before expected 
time of endogenous LH surge (A, D, G, and J), the day of LH 
surge (B, E, H, and K), and 2 days after LH surge (C, F, I, and 
L). In each periovulatory follicle shown, the antrum (a) is in 
the upper right, granulosa cell (gc) are central, and the ovarian 
stroma (s) is in the lower left portion of the image, 
immunodetection (bright green) of EP1 (A, B, C), EP2 (D, E, 
F), EP3 (G, H, I), and EP4 (J, K, L) in periovulatory follicles 
is shown. No fluorescence was observed when the primary 
antibodies were preabsorbed with the blocking peptide (C, F, 
I, L insets). Ovarian images shown are representative of 2-3 
animals/time point. For all panels, bar=50 |im. 
Appendix 5 
Figure 22. Detection of uPA protein in monkey 
periovulatory follicles and kidney. Ovaries were obtained 
from monkeys experiencing controlled ovarian stimulation. 
Immunodetection (bright green) of uPA in monkey ovary 
(A, B) is shown after 0 hour (A) and 36 hours (B) of 
exposure to hCG in vivo. Monkey kidney tissue sections (C) 
were used as positive control. For both ovary and kidney, 
uPA protein was detectable in the walls of blood vessels (v). 
For panels A and B the orientation of the ovarian stroma (s), 
granulosa cells (gc), and the antrum (a) is the same. For all 
panels, bar in panel A=400 urn. Ovarian images are 
representative of 3 animals/time point. 
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Figure 23. Immunofluorescent detection of tPA and PAI-1 proteins in cultured 
granulosa cells. Granulosa cells obtained from animals undergoing controlled 
ovarian stimulation before hCG administration were maintained in vitro with no 
treatment (A-C and G-I) or with hCG (D-F and J-L). After 12 (A, D, G, and J), 
24 (B, E, H, and K), and 36 (C, F, I, and L) hours in culture the cells were 
formalin fixed and analyzed for immunofluorescent detection of tPA (A-F) and 
PAI-1 (G-L) proteins. Immunodetection appears green; nuclei are counterstained 
red. All images are representative of 4-5 animals/treatment. For all images, use 
bar in panel A=20 um. 
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Figure 24. tPA and PAI-1 mRNA in cultured 
periovulatory granulosa cells. Granulosa cells obtained 
before hCG administration were cultured without 
(control) or with hCG+indomethacin. After 24 hours, 
PGE2 or EP receptor selective agonists were added and 
the cells were cultured for additional 12 hours. tPA (A) 
and PAI-1 (B) mRNA levels were determined by real 
time RT-PCR. The ratio of tPA and PAI-1 mRNA to p-
actin mRNA was calculated for all samples. Data 
presented show the mRNA levels in treated cells relative 
to controls (n=4-5/treatment group). In panel A, groups 
with different letters are different by ANOVA and 
Duncan's, p value<0.05. 
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Figure 25. Immunofluorescent detection of EP1, EP2, 
and EP3 receptors in cultured monkey granulosa cells. 
Granulosa cells obtained before hCG administration (0 
hour) were cultured with hCG+indomethacin for 36 
hours. Immunofluorescent analysis was performed with 
antibodies against EP1 (A), EP2 (B), and EP3 (C). EP 
receptor immunodetection appears as bright green 
staining around nuclei stained red with propidium iodide. 
EP receptor detection was absent when primary 
antibodies against EP1 (D), EP2 (E), and EP3 (F) were 
pre-incubated with respective blocking peptides. For all 
images, use bar in panel A=20 urn. 
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A Desintegrin and Metalloprotease Domain with 
Thrombospondin Motifs 
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Follicle Stimulating Hormone 
Guanosine Diphosphate 
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Guanosine Triphosphate 






Non Steroidal Anti Inflammatory Drug 
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Plasminogen Activator Inhibitor 




Prostaglandin E Synthase 
Prostaglandin F 2a 
Protein Kinase A 
Protein Kinase C 
Phospholipase A2 
Phospholipase C 
Pregnant Mare Serum Gonadotropin 
Polymerase Chain Reaction 
Reverse Transcription 
Tissue Inhibitor of Matrix Metalloproteases 
Tissue Type Plasminogen Activator 
Urokinase Type Plasminogen Activator 
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